<SEC-DOCUMENT>0001193125-22-078284.txt : 20220317
<SEC-HEADER>0001193125-22-078284.hdr.sgml : 20220317
<ACCEPTANCE-DATETIME>20220317160215
ACCESSION NUMBER:		0001193125-22-078284
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20220317
DATE AS OF CHANGE:		20220317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-263370
		FILM NUMBER:		22748415

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d303279d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)<BR>Registration No. 333-263370 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROSPECTUS SUPPLEMENT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>(To prospectus dated March&nbsp;14, 2022)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$75,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g303279g04a37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a sales
agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our
common stock, $0.0001 par value per share, having an aggregate offering price of up to $75,000,000 from time to time through Cowen acting as agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TERN.&#148; On March&nbsp;14, 2022 the last reported sale price of our common stock on the Nasdaq Global Select Market was $3.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus will be made in sales deemed to be &#147;at the market
offerings&#148; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act. Cowen is not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable
efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cowen and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation to Cowen for sales of common stock pursuant to the sales agreement will be an amount equal to 3% of the gross proceeds of any shares of
common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cowen will be deemed
to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our business and an investment in our common stock involve significant risks. These risks are described under the caption &#147;<A HREF="#stx303279_5">Risk Factors
</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-12</FONT> of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy
or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Cowen
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;17, 2022 </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_2">MARKET, INDUSTRY AND OTHER DATA</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_3">PROSPECTUS SUPPLEMENT SUMMARY</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_4">THE OFFERING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_5">RISK FACTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_6">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_7">USE OF PROCEEDS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_8">DILUTION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_9">PLAN OF DISTRIBUTION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_10">LEGAL MATTERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_11">EXPERTS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_12">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#stx303279_13">INFORMATION INCORPORATED BY REFERENCE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_3">ABOUT TERNS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_10">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a registration statement that we have filed with the U.S. Securities and Exchange Commission, or the SEC, utilizing a
&#147;shelf&#148; registration process. By using a shelf registration statement, we may offer shares of our common stock having an aggregate offering price of up to $75,000,000 from time to time under this prospectus supplement at prices and on
terms to be determined by market conditions at the time of offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We provide information to you about this offering of shares of our common stock in
two separate documents that are bound together: (1)&nbsp;this prospectus supplement, which describes the specific details regarding this offering; and (2)&nbsp;the accompanying prospectus, which provides general information, some of which may not
apply to this offering. Generally, when we refer to this &#147;prospectus,&#148; we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on this
prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in this prospectus supplement&#151;the
statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and Cowen has not, authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus
supplement, the accompanying prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and Cowen take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. We are not, and Cowen is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction where an offer or solicitation is not authorized or in which the person making that offer or
solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by
reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of
operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we may authorize
for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled
&#147;Where You Can Find More Information&#148; and &#147;Information Incorporated by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering to sell, and seeking offers to
buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute,
and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or
solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to &#147;Terns,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus, we mean
Terns Pharmaceuticals, Inc., unless otherwise specified. When we refer to &#147;you,&#148; we mean the holders of common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Terns,&#148; &#147;Terns Pharmaceuticals,&#148; the Terns logo and other trademarks, trade names or service marks of Terns Pharmaceuticals, Inc.
appearing in this prospectus are the property of Terns Pharmaceuticals, Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_2"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, including the information incorporated by reference herein, contains estimates, projections and other information concerning our
industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties
and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys,
studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we
refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary provides a general overview of selected information and does not contain all of the information you should consider before buying our common
stock. Therefore, you should read the entire prospectus supplement, accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering carefully, including the information incorporated by
reference herein and therein, before deciding to invest in our common stock. Investors should carefully consider the information set forth under &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-12</FONT> of this
prospectus supplement and in the documents incorporated by reference into this prospectus supplement. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Terns Pharmaceuticals, Inc.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis (NASH) and
obesity. Our approach is to develop drug candidates based on mechanisms of action that have achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in clinical trials. Our most advanced drug
candidates are under development for the treatment of NASH using clinically-validated and complementary mechanisms of action to drive meaningful clinical benefits for patients. In our NASH programs, these mechanisms have demonstrated significant
improvements on histological and <FONT STYLE="white-space:nowrap">non-invasive</FONT> markers of the disease, though no drug has been approved for the treatment of NASH in the United States or Europe. In addition, by developing combination
therapies, we are aiming to expand the reach of our single-agent drug candidates through improved response rates, better tolerability and improved compliance as compared to monotherapy regimens. We also have an oral small-molecule glucagon-like <FONT
STYLE="white-space:nowrap">peptide-1</FONT> receptor <FONT STYLE="white-space:nowrap">(GLP-1R)</FONT> agonist in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development that may target metabolic diseases such as obesity as well as NASH.
Beyond NASH, we plan to explore other indications with high unmet need using our pipeline drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced program is <FONT
STYLE="white-space:nowrap">TERN-101,</FONT> a liver-distributed, <FONT STYLE="white-space:nowrap">non-bile</FONT> acid Farnesoid X Receptor (FXR) agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability
profile across multiple clinical trials. In June 2021, we announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> data from our Phase 2a LIFT Study of <FONT STYLE="white-space:nowrap">TERN-101</FONT> in NASH patients. In the LIFT Study, <FONT
STYLE="white-space:nowrap">TERN-101</FONT> was generally well-tolerated with a similar incidence of adverse events (AEs) across treatment groups. There were no treatment-related serious adverse events, and no patient discontinued <FONT
STYLE="white-space:nowrap">TERN-101</FONT> due to any adverse event, including pruritus, or itching. Multiple secondary and exploratory endpoints were also evaluated, including changes in liver fibro-inflammation measured by magnetic resonance
imaging (MRI) corrected T1 (cT1), liver fat content by MRI proton density fat fraction <FONT STYLE="white-space:nowrap">(MRI-PDFF),</FONT> pharmacodynamic parameters, and serum NASH biomarkers. We believe
<FONT STYLE="white-space:nowrap">TERN-101</FONT> is the first FXR agonist product candidate to show significant improvements in cT1, an imaging marker of liver inflammation and fibrosis linked to clinical outcomes, in a <FONT
STYLE="white-space:nowrap">12-week</FONT> placebo-controlled clinical trial. In light of the positive results, we plan to initiate a Phase 2a clinical trial in NASH patients including both monotherapy and combination arms of <FONT
STYLE="white-space:nowrap">TERN-101</FONT> and <FONT STYLE="white-space:nowrap">TERN-501</FONT> in the first half of 2022 with <FONT STYLE="white-space:nowrap">top-line</FONT> data expected in the second half of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second clinical stage program, <FONT STYLE="white-space:nowrap">TERN-201,</FONT> is a highly selective inhibitor of Vascular Adhesion <FONT
STYLE="white-space:nowrap">Protein-1</FONT> <FONT STYLE="white-space:nowrap">(VAP-1).</FONT> We expect to announce <FONT STYLE="white-space:nowrap">top-line</FONT> data from Part 1 of our Phase 1b AVIATION trial of
<FONT STYLE="white-space:nowrap">TERN-201</FONT> in NASH patients in March 2022. We initiated Part 2 of our AVIATION trial in the first quarter of 2022 with <FONT STYLE="white-space:nowrap">top-line</FONT> data expected in the second half of 2022.
We are also evaluating the potential to <FONT STYLE="white-space:nowrap">co-administer</FONT> <FONT STYLE="white-space:nowrap">TERN-201</FONT> in combination with a metabolically active NASH treatment. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third clinical stage program is <FONT STYLE="white-space:nowrap">TERN-501,</FONT> a
Thyroid Hormone Receptor beta <FONT STYLE="white-space:nowrap">(THR-&szlig;)</FONT> agonist with high metabolic stability, enhanced liver distribution and greater selectivity for <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> compared to other <FONT
STYLE="white-space:nowrap">THR-&szlig;</FONT> agonists in development. In November 2021, we announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> data from a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">TERN-501</FONT> in
healthy volunteers with mildly elevated <FONT STYLE="white-space:nowrap">low-density</FONT> lipoprotein (LDL) cholesterol. In the single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, <FONT STYLE="white-space:nowrap">TERN-501</FONT>
was generally well-tolerated with a similar incidence of AEs across all <FONT STYLE="white-space:nowrap">TERN-501</FONT> treatment groups and placebo. All AEs were mild to moderate with no apparent dose relationship, with no treatment-emergent
serious AEs and no discontinuations of study or study drug due to any AE. Significant effects on sex hormone binding globulin (SHBG), a key pharmacodynamic marker of <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> engagement linked to NASH
histologic efficacy, were observed following treatment with <FONT STYLE="white-space:nowrap">TERN-501.</FONT> The SHBG increases observed with 14 days of <FONT STYLE="white-space:nowrap">TERN-501</FONT> treatment were significant, dose dependent and
have been associated with robust reductions in <FONT STYLE="white-space:nowrap">MRI-PDFF</FONT> and NAFLD Activity Score in a precedent late-stage clinical NASH trial of another THR<B>-</B>&szlig; agonist. Preliminary pharmacokinetic results support
the <FONT STYLE="white-space:nowrap">co-administration</FONT> of <FONT STYLE="white-space:nowrap">TERN-101</FONT> and <FONT STYLE="white-space:nowrap">TERN-501</FONT> in NASH patients, with no apparent need for dose adjustment. We plan to initiate a
Phase 2a clinical trial in NASH patients including both monotherapy and combination arms of <FONT STYLE="white-space:nowrap">TERN-101</FONT> and <FONT STYLE="white-space:nowrap">TERN-501</FONT> in the first half of 2022 with <FONT
STYLE="white-space:nowrap">top-line</FONT> data expected in the second half of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also developing an oral small-molecule <FONT
STYLE="white-space:nowrap">GLP-1R</FONT> agonist. Synthetic <FONT STYLE="white-space:nowrap">GLP-1</FONT> peptides have been approved for diabetes and obesity, which are conditions that often accompany NASH. We designated a development candidate for
our <FONT STYLE="white-space:nowrap">GLP-1R</FONT> program as <FONT STYLE="white-space:nowrap">TERN-601</FONT> in the fourth quarter of 2021. We plan to engage in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities for <FONT
STYLE="white-space:nowrap">TERN-601</FONT> with the goal of initiating a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NASH is a severe form of <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> fatty liver disease, or NAFLD, that affects up to
20&nbsp;million people in the United States, and up to 5% of the global population, and for which there is currently no approved therapy in the United States or Europe. In a study published in <I>Hepatology</I> in 2018, lifetime costs of treating
and managing NASH patients in the United States in 2017 were estimated to be over $220&nbsp;billion, in the absence of approved therapies. NASH is a multifaceted disease that involves three distinct pathogenic hepatic disease processes: steatosis,
inflammation and fibrosis. In addition to these three disease processes, NASH patients often exhibit elevated levels of glucose and atherogenic lipids, are overweight or obese and accumulate excessive lipotoxic fat. Severe progression of NASH can
lead to cirrhosis, decompensated liver disease and increased risk for hepatic carcinoma and liver-related mortality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obesity is caused by
weight gain resulting from an energy imbalance in the body driven by a greater consumption of calories than those expended. Declared a global epidemic by the World Health Organization over 20 years ago, obesity has continued to rise significantly
around the world. According to the National Center for Health Statistics, a third of U.S. adults 20 years of age and older are obese. Obesity has been shown to increase the risks of many diseases and conditions, such as hypertension, dyslipidemia,
type 2 diabetes, coronary heart disease, stroke, gallbladder disease, arthritis, sleep apnea and some cancers (endometrial, breast, and colon). According to a recent study, obesity was associated with an estimated $260&nbsp;billion in annual
healthcare expenditures in the United States. <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonists, which have been shown to address insulin resistance, a hallmark of metabolic syndrome, represent an emerging class of therapies used to
achieve weight loss. Consensus estimates forecast worldwide sales of <FONT STYLE="white-space:nowrap">GLP-1</FONT> therapeutics and its combinations to exceed $16&nbsp;billion in 2021 and grow to over $30&nbsp;billion by 2026. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced
wholly owned, single-agent drug candidates are under development for the treatment of NASH using complementary mechanisms of action to drive meaningful clinical benefits for patients. We also have a wholly owned drug candidate in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development that may target metabolic diseases such as obesity as well as NASH. In addition to our single-agent drug candidates, our wholly owned pipeline includes combination therapy candidates that
are intended to address each of the distinct pathogenic disease processes of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
NASH, while improving the overall metabolic profile of patients. Beyond NASH and obesity, we plan to explore other indications with high unmet need using our wholly owned drug candidates. In
addition to our wholly owned drug candidates, we have an allosteric <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> tyrosine kinase inhibitor with an active IND in China, which is being developed in the greater China region by our development
partner. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g303279g05b43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pipeline Candidates for NASH and Metabolic Diseases:</I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">TERN-101</FONT></B> is a liver-distributed,
<FONT STYLE="white-space:nowrap">non-bile</FONT> acid Farnesoid X Receptor, or FXR, agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only
transient FXR activation in the intestine. FXR is a nuclear receptor primarily expressed in the liver, intestine and kidneys. FXR regulates hepatic expression of various genes involved in lipid metabolism, inflammation and fibrosis. Clinical trials
of other FXR agonists have demonstrated significant histological NASH improvements but have also resulted in pruritus and adverse lipid changes. These safety and tolerability issues have been observed in clinical trials for other FXR agonists and
have generally been regarded as dose-limiting toxicities, which are suboptimal for patients and can lead to treatment discontinuation. In June 2021, we announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> data from our Phase 2a LIFT
Study of <FONT STYLE="white-space:nowrap">TERN-101</FONT> in NASH patients. In the LIFT Study, <FONT STYLE="white-space:nowrap">TERN-101</FONT> was generally well-tolerated with a similar incidence of AEs across treatment groups. There were no
treatment-related serious adverse events, and no patient discontinued <FONT STYLE="white-space:nowrap">TERN-101</FONT> due to any adverse event, including pruritus. We believe <FONT STYLE="white-space:nowrap">TERN-101</FONT> is the first FXR agonist
product candidate to show significant improvements in cT1, an imaging marker of liver inflammation and fibrosis linked to clinical outcomes, in a <FONT STYLE="white-space:nowrap">12-week</FONT> placebo-controlled clinical trial. In light of the
positive results, we plan to initiate a Phase 2a clinical trial in NASH patients including both monotherapy and combination arms of <FONT STYLE="white-space:nowrap">TERN-101</FONT> and <FONT STYLE="white-space:nowrap">TERN-501</FONT> in the first
half of 2022 with <FONT STYLE="white-space:nowrap">top-line</FONT> data expected in the second half of 2023. We received Fast Track designation from the U.S. Food and Drug Administration, or the FDA, for
<FONT STYLE="white-space:nowrap">TERN-101</FONT> for the treatment of NASH in October 2019. Fast Track designation does not guarantee an accelerated review by the FDA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">TERN-201</FONT></B> is a highly-selective inhibitor of Vascular Adhesion <FONT
STYLE="white-space:nowrap">Protein-1,</FONT> or <FONT STYLE="white-space:nowrap">VAP-1,</FONT> that has demonstrated sustained target engagement in clinical trials without the <FONT STYLE="white-space:nowrap">off-target</FONT> liabilities associated
with other <FONT STYLE="white-space:nowrap">VAP-1</FONT> inhibitors in development. <FONT STYLE="white-space:nowrap">VAP-1</FONT> facilitates the deceleration, binding, and transmigration of leukocytes from the bloodstream into the liver and
produces reactive oxygen species that promote liver inflammation and fibrosis. <FONT STYLE="white-space:nowrap">VAP-1</FONT> has been shown to be over-expressed in the livers of NASH patients in response to local lipotoxicity and liver injury. In a
Phase 2a clinical trial of another developer&#146;s <FONT STYLE="white-space:nowrap">VAP-1</FONT> inhibitor in NASH patients, 12 weeks of administration demonstrated </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
significant, dose-dependent improvements in NASH biomarkers, providing clinical proof of concept for <FONT STYLE="white-space:nowrap">VAP-1</FONT> inhibition in NASH. In our Phase 1a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> (SAD/MAD) clinical trial in 61 healthy subjects, <FONT STYLE="white-space:nowrap">TERN-201</FONT> was shown to fully suppress plasma <FONT
STYLE="white-space:nowrap">VAP-1</FONT> activity at all of the doses we evaluated. <FONT STYLE="white-space:nowrap">TERN-201</FONT> was selected for development over other discovery candidates because it is highly specific for <FONT
STYLE="white-space:nowrap">VAP-1</FONT> inhibition and has minimal potential for <FONT STYLE="white-space:nowrap">off-target</FONT> effects. We expect to announce <FONT STYLE="white-space:nowrap">top-line</FONT> data from Part 1 of our Phase 1b
AVIATION Trial of <FONT STYLE="white-space:nowrap">TERN-201</FONT> in NASH patients in March 2022. We initiated Part 2 of our AVIATION trial in the first quarter of 2022 with <FONT STYLE="white-space:nowrap">top-line</FONT> data expected in the
second half of 2022. We are also evaluating the potential to <FONT STYLE="white-space:nowrap">co-administer</FONT> <FONT STYLE="white-space:nowrap">TERN-201</FONT> in combination with a metabolically active NASH treatment. We received Fast Track
designation from the FDA for <FONT STYLE="white-space:nowrap">TERN-201</FONT> for the treatment of NASH in August 2020. Fast Track designation does not guarantee an accelerated review by the FDA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">TERN-501</FONT></B> is a Thyroid Hormone Receptor beta, or <FONT
STYLE="white-space:nowrap">THR-&szlig;,</FONT> agonist with high metabolic stability, enhanced liver distribution and greater selectivity for <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> compared to other
<FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> agonists in development. Agonism of <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism.
As a result, <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. <FONT STYLE="white-space:nowrap">TERN-501</FONT>
has high liver distribution and is <FONT STYLE="white-space:nowrap">23-fold</FONT> more selective for <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> than for <FONT STYLE="white-space:nowrap">THR-&#945;</FONT> activation, thereby minimizing the
risk of cardiotoxicity and other <FONT STYLE="white-space:nowrap">off-target</FONT> effects associated with <FONT STYLE="white-space:nowrap">non-selective</FONT> THR stimulation. Finally, <FONT STYLE="white-space:nowrap">TERN-501</FONT> has been
designed to be metabolically stable and is therefore expected to have little pharmacokinetic variability and a low clinical dose, making it an attractive candidate for use in fixed-dose combinations for NASH treatment. In November 2021, we announced
positive <FONT STYLE="white-space:nowrap">top-line</FONT> data from a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">TERN-501</FONT> in healthy volunteers with mildly elevated LDL cholesterol. In the SAD and MAD cohorts, <FONT
STYLE="white-space:nowrap">TERN-501</FONT> was generally well-tolerated with a similar incidence of AEs across all <FONT STYLE="white-space:nowrap">TERN-501</FONT> treatment groups and placebo. All AEs were mild to moderate with no apparent dose
relationship, with no treatment-emergent serious AEs and no discontinuations of study or study drug due to any AE. Significant effects on SHBG, a key pharmacodynamic marker of <FONT STYLE="white-space:nowrap">THR-&szlig;</FONT> engagement linked to
NASH histologic efficacy, were observed following treatment with <FONT STYLE="white-space:nowrap">TERN-501.</FONT> The SHBG increases observed with 14 days of <FONT STYLE="white-space:nowrap">TERN-501</FONT> treatment were significant, dose
dependent and have been associated with robust reductions in <FONT STYLE="white-space:nowrap">MRI-PDFF</FONT> and NAFLD Activity Score in a precedent late-stage clinical NASH trial. Preliminary pharmacokinetic results support the <FONT
STYLE="white-space:nowrap">co-administration</FONT> of <FONT STYLE="white-space:nowrap">TERN-101</FONT> and <FONT STYLE="white-space:nowrap">TERN-501</FONT> in NASH patients, with no apparent need for dose adjustment. We plan to initiate a Phase 2a
clinical trial in NASH patients including both monotherapy and combination arms of <FONT STYLE="white-space:nowrap">TERN-101</FONT> and <FONT STYLE="white-space:nowrap">TERN-501</FONT> in the first half of 2022 with
<FONT STYLE="white-space:nowrap">top-line</FONT> data expected in the second half of 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">TERN-601</FONT></B> is our small-molecule Glucagon-Like <FONT
STYLE="white-space:nowrap">Peptide-1</FONT> Receptor, or <FONT STYLE="white-space:nowrap">GLP-1R,</FONT> agonist program that is intended to be orally administered for NASH and metabolic diseases such as obesity. Obesity is a chronic disease that is
increasing in prevalence in adults, adolescents and children and is often defined by having an elevated body mass index (BMI). Mechanisms that contribute to increased weight include sedentary lifestyles, increased calorie intake and medications such
as insulins and antipsychotics. Insulin resistance, a hallmark of metabolic syndrome, also plays a key role in obesity. <FONT STYLE="white-space:nowrap">GLP-1</FONT> offers multiple benefits including increased insulin secretion to the pancreas,
reduced glucagon secretion in the liver, slowed gastric emptying into the gut, increased sense of satiety in the brain and reduced inflammation. Synthetic <FONT STYLE="white-space:nowrap">GLP-1</FONT> peptides have been approved for obesity and
diabetes, which are conditions often accompanying NASH. However, approved synthetic <FONT STYLE="white-space:nowrap">GLP-1</FONT> peptides may require higher doses and frequent subcutaneous injections. This injectable route of administration is
likely to limit their use in NASH patients, particularly if efficacious oral NASH treatments become available. Our <FONT STYLE="white-space:nowrap">GLP-1R</FONT> program has identified several potentially suitable small-molecule scaffolds. We have
optimized these series of compounds and identified structures that we believe are suitable for oral administration as a single-agent or in combination with other drug candidates within our pipeline. We
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
designated a development candidate for our <FONT STYLE="white-space:nowrap">GLP-1R</FONT> program as <FONT STYLE="white-space:nowrap">TERN-601</FONT> in the fourth quarter of 2021. We plan to
engage in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities for <FONT STYLE="white-space:nowrap">TERN-601</FONT> with the goal of initiating a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial in 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Combinations
for NASH: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several prior clinical trials evaluating single-agent therapies for NASH have shown only moderate histological improvements
and exhibited tolerability issues with some of these agents at high doses. We believe that developing combination therapies that target multiple mechanistic pathways and improve the overall metabolic profile of NASH patients will drive improved
outcomes for NASH patients while mitigating potential tolerability concerns and improving compliance as compared with monotherapy regimens. We are well-positioned to develop multiple combination therapies for NASH with our extensive experience in
combination drug development and the ability to leverage our pipeline of wholly owned single-agents that we believe are suitable for orally administered combination development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that therapies targeting steatosis <FONT STYLE="white-space:nowrap">(TERN-101</FONT> and
<FONT STYLE="white-space:nowrap">TERN-501),</FONT> inflammation <FONT STYLE="white-space:nowrap">(TERN-101</FONT> and <FONT STYLE="white-space:nowrap">TERN-201)</FONT> and fibrosis <FONT STYLE="white-space:nowrap">(TERN-101</FONT> and <FONT
STYLE="white-space:nowrap">TERN-201)</FONT> in tandem, have the potential to provide greater resolution of NASH and improvement in related clinical outcomes. Clinical trials of <FONT STYLE="white-space:nowrap">GLP-1</FONT> agonists <FONT
STYLE="white-space:nowrap">(TERN-601)</FONT> in NASH patients have shown that a greater proportion of patients achieved NASH resolution without worsening of fibrosis and experienced improvement of other metabolic outcomes such as weight loss and
glycemic control as compared to placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to initiate a Phase 2a clinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial evaluating a combination of <FONT STYLE="white-space:nowrap">TERN-101</FONT> and <FONT STYLE="white-space:nowrap">TERN-501</FONT> in NASH patients in the first half of 2022 with <FONT
STYLE="white-space:nowrap">top-line</FONT> data expected in the second half of 2023. We are also assessing the potential utility of combinations of <FONT STYLE="white-space:nowrap">TERN-201</FONT> with assets inside and outside of our pipeline.
Given the strength of our internal resources and capabilities, we have the flexibility to independently advance our combination therapies without the need for a <FONT STYLE="white-space:nowrap">co-development</FONT> partner at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Pipeline Candidates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">TRN-000632</FONT> is a potent, allosteric <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> tyrosine kinase inhibitor targeting the ABL myristoyl pocket that is in development for chronic myeloid leukemia, or CML. We <FONT
STYLE="white-space:nowrap">out-licensed</FONT> <FONT STYLE="white-space:nowrap">TRN-000632</FONT> to Hansoh Pharmaceuticals for development in the greater China region, while retaining all rights worldwide outside of greater China. <FONT
STYLE="white-space:nowrap">TRN-000632</FONT> is referred to by Hansoh Pharmaceuticals as <FONT STYLE="white-space:nowrap">HS-10382.</FONT> In January 2022, the National Medical Products Administration of the People&#146;s Republic of China granted a
clinical trial notice (equivalent to an IND in the United States) for <FONT STYLE="white-space:nowrap">TRN-000632</FONT> tablets in CML. We intend to explore strategic and partnership options for the development and commercialization of <FONT
STYLE="white-space:nowrap">TRN-000632</FONT> outside of greater China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to develop and commercialize differentiated monotherapies and combination therapies for serious diseases such as NASH and obesity.
Key elements of our strategy to achieve this goal include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Develop improved drug candidates targeting clinically-validated mechanisms of action. </B>We are developing a
portfolio of small-molecule drug candidates targeting clinically-validated mechanisms of action for the treatment of serious diseases such as NASH and obesity. The mechanisms of action targeted by the current drug candidates in our pipeline
portfolio are the same mechanisms of action targeted by other drug candidates that have achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in clinical trials. However, these clinical trials have
also highlighted an opportunity for us to meaningfully improve the efficacy, safety and tolerability of therapies utilizing these mechanisms. Based on this premise, we are advancing multiple drug candidates we believe have the potential to deliver
better clinical outcomes in a high proportion of patients in the target indication as either single-agent or combination therapies. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage <FONT STYLE="white-space:nowrap">non-invasive</FONT> biomarkers to rapidly advance our single-agent
drug candidates. </B>We are advancing our single-agent drug candidates through clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trials on an expedited basis by using relevant <FONT
STYLE="white-space:nowrap">non-invasive</FONT> biomarkers in our Phase 1 and Phase 2 clinical trials to efficiently confirm and benchmark target engagement or efficacy without the need for liver biopsies. We are looking to pioneer the use of <FONT
STYLE="white-space:nowrap">non-invasive</FONT> technologies (NIT) as potential novel surrogate endpoints for NASH, and are pursuing multiple avenues to achieve this outcome in collaboration with the broader NASH community. We believe this approach
may enable us to accelerate enrollment in our clinical trials and achieve significantly shorter development timelines. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance our portfolio of combination therapy candidates for the treatment of NASH. </B>In addition to
developing our single-agent drug candidates,<B> </B>we are evaluating and developing fixed-dose combination therapies to address the multiple disease processes of NASH, while improving the overall metabolic profile of NASH patients. We believe
developing combination therapies that target multiple mechanistic pathways and improve the overall metabolic profile of NASH patients will drive improved outcomes for NASH patients while mitigating potential tolerability concerns and improving
compliance as compared with monotherapy regimens. The outcomes of our monotherapy biomarker-based clinical trials will further inform our decision to pursue the utility of our drug candidates as monotherapies or in fixed-dose-combinations that we
believe have synergistic therapeutic effect and well-balanced safety profiles. We have identified and are advancing our first combination therapy candidate for NASH, involving a combination of <FONT STYLE="white-space:nowrap">TERN-101</FONT> and <FONT
STYLE="white-space:nowrap">TERN-501,</FONT> and expect to initiate a Phase 2a clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in the first half of 2022 with <FONT
STYLE="white-space:nowrap">top-line</FONT> data expected in the second half of 2023. We are also evaluating the potential to <FONT STYLE="white-space:nowrap">co-administer</FONT> <FONT STYLE="white-space:nowrap">TERN-201,</FONT> a potent
anti-inflammatory and anti-fibrotic agent, in combination with a metabolically active NASH treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance our earlier stage program and expand applications for our existing drug candidates. </B>We have
identified a <FONT STYLE="white-space:nowrap">GLP-1R</FONT> small-molecule agonist, designated <FONT STYLE="white-space:nowrap">TERN-601,</FONT> with the potential to address metabolic processes involved in the pathogenesis of obesity, NASH and
other metabolic diseases. Our <FONT STYLE="white-space:nowrap">TERN-601</FONT> program is targeting the development of a product for once-daily oral administration to overcome the limitations of existing <FONT STYLE="white-space:nowrap">GLP-1</FONT>
agonists and enable widespread use in patients with obesity, NASH and other diseases. We plan to engage in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities for <FONT STYLE="white-space:nowrap">TERN-601</FONT> with the goal of
initiating a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial in 2023. Beyond obesity and NASH, our goal is to maximize the commercial potential of our existing drug candidates by
exploring additional indications supported by their underlying biology and mechanism. We will maintain a focused and disciplined strategy in evaluating potential <FONT STYLE="white-space:nowrap">follow-on</FONT> indications that may merit further
advancement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Independently develop and commercialize our drug candidates in indications and geographies where we believe we
can maximize the value and benefit to patients. </B>We have a disciplined strategy to maximize the value of our pipeline by retaining development and commercialization rights to those drug candidates, indications and geographies that we believe we
can ultimately commercialize successfully on our own if they are approved. We plan to collaborate on drug candidates, such as <FONT STYLE="white-space:nowrap">TRN-000632,</FONT> that we believe have promising utility in disease areas, patient
populations or geographies that are better served by the resources or specific expertise of other biopharmaceutical companies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Terns </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the Cayman Islands on December&nbsp;9, 2016. On December&nbsp;29, 2020, we effected a <FONT
STYLE="white-space:nowrap">de-registration</FONT> under the Cayman Islands Companies Law (2020 Revision) and a domestication under Section&nbsp;388 of the Delaware General Corporation Law (by means of filing a certificate of domestication with the
Secretary of State of Delaware), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 1065 East Hillsdale Boulevard, Suite 100,
Foster City, California 94404, and our telephone number is (650) <FONT STYLE="white-space:nowrap">525-5535.</FONT> Our corporate website address is www.ternspharma.com. Information contained on, or accessible through, our website shall not be deemed
incorporated into and is not a part of this prospectus or the registration statement of which it forms a part. We have included our website in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging
growth company until the earliest of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of the consummation of our initial public offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue
of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934,
as amended, or the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such
year or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. An emerging growth company may take advantage of specified
reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will present in this prospectus only two years of audited consolidated financial statements, plus unaudited
condensed consolidated financial statements for any interim period, and related management&#146;s discussion and analysis of financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will avail ourselves of the exemption from the requirement to obtain an attestation and report from our
auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will provide less extensive disclosure about our executive compensation arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will not require stockholder <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive
compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the information contained herein may be different than the
information you receive from our competitors that are public companies or other public companies in which you hold stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some
accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to
adopt new or revised accounting standards as other public companies that are not emerging growth companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Stock Offered by Us <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares of our common stock having an aggregate offering price of up to $75,000,000.<BR></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Stock Outstanding After This Offering</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to 50,269,271&nbsp;shares, assuming sales at a price of $3.00&nbsp;per share, which was the closing price of our common stock on the Nasdaq Global Select Market on March&nbsp;14, 2022. The actual number of shares issued will vary
depending on the sales price under this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Manner of Offering</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;At the market offering&#148; that may be made from time to time through our sales agent, Cowen and Company, LLC. See &#147;Plan of Distribution&#148; on page <FONT STYLE="white-space:nowrap">S-18.</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We intend to use the net proceeds from this offering, if any, for general corporate purposes, which may include, among other things, working capital and funding research and development, and capital expenditures including clinical
program progression. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-16.</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk Factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You should read the &#147;Risk Factors&#148; section of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to purchase
shares of our common stock.</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Symbol on the Nasdaq Global Select Market</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;TERN&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding after this offering is based on 25,269,271 shares of common stock
outstanding as of December&nbsp;31, 2021 and excludes, in each case as of December&nbsp;31, 2021: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,577,485 shares of our common stock issuable upon the exercise of stock options to purchase common stock that
were outstanding as of December&nbsp;31, 2021, with a weighted average exercise price of $9.72 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,138,622 shares of common stock reserved for issuance pursuant to future awards under our 2021 Incentive Award
Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan (such as the 1,263,463 shares of common stock automatically added to this plan on January&nbsp;1, 2022); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">240,000 shares of common stock reserved for issuance pursuant to future awards under our Employee Stock Purchase
Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan (such as the 252,692 shares of common stock automatically added to this plan on January&nbsp;1, 2022).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, unless we specifically state otherwise, all information in this prospectus assumes no exercise of outstanding stock
options subsequent to December&nbsp;31, 2021. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should consider carefully the risks described below and discussed under the section captioned &#147;Risk Factors&#148; contained in our
annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as updated by our subsequent filings under the Exchange Act, each of which is incorporated by reference in this prospectus supplement in
their entirety, together with other information in this prospectus supplement, and the information and documents incorporated by reference in this prospectus supplement, and any free writing prospectus that we have authorized for use in connection
with this offering before you make a decision to invest in our common stock. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could
cause the trading price of our common stock to decline and you may lose all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may
also affect our business operations. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant
return. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion over the use of proceeds from this offering. We intend to use the net proceeds,
if any, from this offering for general corporate purposes, which may include, among other things, working capital and funding research and development, and capital expenditures including clinical program progression. Our management will have
considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. The net proceeds may be used for corporate
purposes that do not increase our operating results or enhance the value of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution
in the net tangible book value per share of the common stock you purchase. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The price per share of our common stock being offered
may be higher than the net tangible book value per share of our common stock outstanding prior to this offering. After giving effect to the sale of our common stock in the maximum aggregate offering amount of $75.0 million at an assumed offering
price of $3.00 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on March&nbsp;14, 2022, and after deducting estimated offering commissions and estimated fees payable by us, our net tangible book value as
of December&nbsp;31, 2021 would have been $232.7 million, or $4.63 per share of common stock. This represents an immediate decrease in the net tangible book value of $1.71 per share to our existing stockholders. While you may experience immediate
accretion under the assumed offering price of $3.00, if you purchase shares of our common stock at a price that is above the net tangible book value per share, you will experience immediate dilution. See the section entitled &#147;Dilution&#148;
below for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future
dilution as a result of future equity offerings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we expect to in the future offer additional
shares of our common stock or other securities convertible into or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater
than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common
stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering. As of December&nbsp;31, 2021, approximately 5.0&nbsp;million shares of common
stock that are either subject to outstanding options, issuable upon vesting of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding restricted stock units, or reserved for future issuance under our equity incentive plans are eligible for sale in the public market to the extent permitted by the provisions of
various vesting schedules and Rule 144 and Rule 701 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The actual number of shares we will issue under the sales agreement,
at any one time or in total, is uncertain. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the sales agreement and compliance with applicable
law, we have the discretion to deliver a placement notice to Cowen at any time throughout the term of the sales agreement. The number of shares that are sold by Cowen after delivering a placement notice will fluctuate based on the market price of
the common shares during the sales period and limits we set with Cowen. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict
the number of shares that will be ultimately issued.<B><I> </I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The shares of common stock offered hereby will be sold in &#147;at the
market&#148; offerings, and investors who buy shares of our common stock at different times will likely pay different prices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors who purchase shares of our common stock in this offering at different times will likely pay different prices, and so may experience
different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares of our common stock sold in this offering. In addition, subject to
the final determination by our board of directors, there is no minimum or maximum sales price for shares of our common stock to be sold in this offering. Investors may experience a decline in the value of the shares of common stock they purchase in
this offering as a result of sales made at prices lower than the prices they paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_6"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement contains forward-looking statements concerning our business, operations and financial performance and condition, as
well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These
statements involve known and unknown risks, uncertainties related to the global COVID 19 pandemic and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you
can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;due,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would,&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are
not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations with regard to the results of our clinical studies, preclinical studies and research and
development programs, including the timing and availability of data from such studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of commencement of future nonclinical studies and clinical trials and research and development
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our clinical and regulatory development plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the potential market size and size of the potential patient populations for our
single-agent and combination therapy candidates and any future single-agent and combination therapy candidates if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to acquire, discover, develop and advance single-agent and combination therapy candidates into, and
successfully complete, clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intentions and our ability to establish collaborations and/or partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals for our single-agent and combination therapy
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and expectations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intentions with respect to the commercialization of our single-agent and combination therapy candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our single-agent and combination therapy candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential effects of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our preclinical and clinical
programs and business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model and strategic plans for our business and single-agent and combination
therapy candidates, including additional indications for which we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish, maintain, protect and enforce for intellectual property rights
covering our single-agent and combination therapy candidates including the projected terms of patent protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our
ability to obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors and our industry, including competing products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement, the accompanying prospectus, and the documents
incorporated by reference herein completely and with the understanding that our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. In light of the significant risks and uncertainties
to which our forward-looking statements are subject, you should not place undue reliance on or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified
timeframe, or at all. We discuss many of these risks in greater detail in the documents incorporated by reference herein, including under the heading &#147;Risk Factors.&#148; These forward-looking statements represent our estimates and assumptions
only as of the dates of this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, and any free writing prospectus, as applicable, regardless of the time of delivery of this prospectus or
any sale of our common stock and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this prospectus
supplement. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $75,000,000 from time to time. The amount of
proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with
Cowen as a source of financing. We intend to use the net proceeds, if any, from this offering for general corporate purposes, which may include, among other things, increasing our working capital and funding research and development and capital
expenditures including clinical program progression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our actual expenditures will depend on numerous factors,
including our development and commercialization efforts with respect to our product candidates, as well as the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes
described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds, if
any, from this offering in short-term, investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of December&nbsp;31, 2021 was approximately $160.3&nbsp;million, or $6.34 per share. Net tangible book value
per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of December&nbsp;31, 2021. Dilution in net tangible book value per share represents the difference
between the amount per share paid by purchasers of shares of common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of our common stock in the aggregate amount of $75.0&nbsp;million in this offering at an assumed offering
price of $3.00, the last reported sale price of our common stock on the Nasdaq Global Select Market on March&nbsp;14, 2022, and after deducting commissions and estimated aggregate offering expenses payable by us, our as adjusted net tangible book
value as of December&nbsp;31, 2021 would have been approximately $232.7 million, or $4.63 per share. This represents an immediate decrease in net tangible book value of $1.71 per share to existing stockholders. While you may experience immediate
accretion under the assumed offering price of $3.00, if you purchase shares of our common stock at a price that is above the net tangible book value per share, you will experience immediate dilution. The following table illustrates the dilution on a
per share basis assuming the assumed offering price is $1.00 above the net tangible book value as of December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Illustrative public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information above is supplied for illustrative purposes only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options or warrants are exercised or outstanding restricted stock awards vest, investors purchasing our common
stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 25,269,271 shares of common stock outstanding as of December&nbsp;31, 2021, and excludes, in each
case as of December&nbsp;31, 2021: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,577,485 shares of our common stock issuable upon the exercise of stock options to purchase common stock that
were outstanding as of December&nbsp;31, 2021, with a weighted average exercise price of $9.72 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,138,622 shares of common stock reserved for issuance pursuant to future awards under our 2021 Incentive Award
Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan (such as the 1,263,463 shares of common stock automatically added to this plan on January&nbsp;1, 2022); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">240,000 shares of common stock reserved for issuance pursuant to future awards under our Employee Stock Purchase
Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan (such as the 252,692 shares of common stock automatically added to this plan on January&nbsp;1, 2022).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a sales agreement with Cowen, under which we may issue and sell from time to time up to $75,000,000 of our common stock through Cowen as
our sales agent. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#147;at the market&#148; offering as defined in Rule 415 under the Securities Act, including sales made directly on the Nasdaq
Global Select Market or any other trading market for our common stock. If authorized by us in writing, Cowen may purchase shares of our common stock as principal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen will offer our common stock subject to the terms and conditions of the sales agreement on a daily basis or as otherwise agreed upon by us and Cowen. We
will designate the maximum amount of common stock to be sold through Cowen on a daily basis or otherwise determine such maximum amount together with Cowen. Subject to the terms and conditions of the sales agreement, Cowen will use its commercially
reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct Cowen not to sell common stock if the sales cannot be effected at or above the price designated by us in any such instruction.
Cowen or we may suspend the offering of our common stock being made through Cowen under the sales agreement upon proper notice to the other party. Cowen and we each have the right, by giving written notice as specified in the sales agreement, to
terminate the sales agreement in each party&#146;s sole discretion at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate compensation payable to Cowen as sales agent is equal to 3%
of the gross sales price of the shares sold through it pursuant to the sales agreement. We have agreed to reimburse Cowen its actual outside legal expenses incurred in connection with this offering, including its FINRA counsel fee, up to an
aggregate of $75,000. We estimate that the total expenses of the offering payable by us, excluding commissions payable to Cowen under the sales agreement, will be approximately $350,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory
organization in connection with the sales, will equal our net proceeds for the sale of such common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen will provide written confirmation to us
following the close of trading on The Nasdaq Global Select Market on each day in which common stock is sold through it as sales agent under the sales agreement. Each confirmation will include the number of shares of common stock sold through it as
sales agent on that day, the volume weighted average price of the shares sold and the net proceeds to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will report at least quarterly the number of
shares of common stock sold through Cowen under the sales agreement, the net proceeds to us and the compensation paid by us to Cowen in connection with the sales of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement for sales of common stock will occur, unless the parties agree otherwise, on the second business day that is also a trading day following the date
on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sales of our common stock on our behalf, Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities
Act, and the compensation paid to Cowen will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and contribution to Cowen against certain liabilities, including liabilities under
the Securities Act. As sales agent, Cowen will not engage in any transactions that stabilize our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq
Global Select Market and trades under the symbol &#147;TERN.&#148; The transfer agent of our common stock is Computershare, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and/or its
affiliates have provided, and may in the future provide, various investment banking and other financial services for us and our affiliates, for which services they have received and, may in the future receive, customary fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the securities offered hereby will be passed upon by our counsel, Latham&nbsp;&amp; Watkins LLP, Menlo Park, California. Cowen
and Company, LLC is being represented in connection with this offering by Davis Polk&nbsp;
&amp; Wardwell LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as set forth in their report which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our financial
statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, of which this prospectus
forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we
are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this
prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has
been filed as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file reports, proxy statements and other information with the SEC under the Exchange Act. The
SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is<I>&nbsp;www.sec.gov</I>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stx303279_13"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with them which means that we can disclose important information to you by
referring you to those documents instead of having to repeat the information in this prospectus supplement and the accompanying prospectus. The information incorporated by reference is considered to be part of this prospectus supplement and the
accompanying prospectus, and later information that we file with the SEC will automatically update and supersede this information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or
superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces that statement. We incorporate by reference the documents listed below and any future information filed (rather than
furnished) with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act between the date of this prospectus and the termination of this offering, provided, however, that we are not incorporating any information furnished under
Item&nbsp;2.02 or Item&nbsp;7.01 of any current report on Form <FONT STYLE="white-space:nowrap">8-K:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022002962/tern-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;7, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022000398/tern-20220119.htm">Form
 <FONT STYLE="white-space:nowrap">8-K</FONT></A> filed with the SEC on January&nbsp;19, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000119312521014462/d328418d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on January&nbsp;22, 2021, including any amendments or reports filed with the SEC for the purposes of updating this description. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These documents may also be accessed on our website at<I>&nbsp;www.ternspharma.com</I>. Except as otherwise
specifically incorporated by reference in this prospectus supplement and the accompanying prospectus, information contained in, or accessible through, our website is not a part of this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to
these documents by writing or telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Terns Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1065 East Hillsdale Blvd., Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Foster City, California 94404 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650) <FONT STYLE="white-space:nowrap">275-4254</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$250,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g303279g04a37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Terns Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell up to $250,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus
provides you with a general description of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities, we will provide a supplement to this prospectus that
contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read
this prospectus and the applicable prospectus supplement before you invest in any of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in
this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of
the securities, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the
sections of this prospectus entitled &#147;About this Prospectus&#148; and &#147;Plan of Distribution&#148; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the
method and terms of the offering of such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#147;<A HREF="#tx303279_4">RISK
FACTORS</A>&#148; ON PAGE 5 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TERN.&#148; On March&nbsp;7, 2022, the last reported sale price of our
common stock on the Nasdaq Global Select Market was $3.14 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is March&nbsp;14, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_3">ABOUT TERNS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_10">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx303279_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148;
registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount of $250,000,000 as described in this prospectus. Each time that we offer and sell
securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free writing
prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus with respect to that
offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable. Before
purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the heading &#147;Where You
Can Find More Information; Incorporation by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any information or to make any
representations other than those contained in, or incorporated by reference into, this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should
assume that the information appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is
accurate only as of the date of that free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial
condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry
statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have
not independently verified this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus, any prospectus supplement or any applicable free writing prospectus may
involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in this prospectus, the applicable prospectus
supplement and any applicable free writing prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to &#147;Terns,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus, we mean Terns
Pharmaceuticals, Inc., unless otherwise specified. When we refer to &#147;you,&#148; we mean the potential holders of the applicable series of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Terns,&#148; &#147;Terns Pharmaceuticals,&#148; the Terns logo and other trademarks, trade names or service marks of Terns Pharmaceuticals, Inc.
appearing in this prospectus are the property of Terns Pharmaceuticals, Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and
trade names in this prospectus may be referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any
indicator that their respective owners will not assert their rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_2"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file reports, proxy
statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is
<I>http://www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our website address is https://<I>www.ternspharma.com</I>. The information on, or accessible through, our website, however, is
not, and should not be deemed to be, a part of this prospectus or any prospectus supplement. We have included our website address as an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the
registration statement. The full registration statement may be obtained from the SEC or us, as provided above. Forms of the indenture and other documents establishing the terms of the offered securities are or may be filed as exhibits to the
registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference
to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by
Reference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will
automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a
statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by
reference our documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the &#147;Exchange Act&#148; in this prospectus,
between the date of this prospectus and the termination of the offering of the securities described in this prospectus. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed below or filed in
the future, that are not deemed &#147;filed&#148; with the SEC, including any Compensation Committee report and performance graph or any information furnished pursuant to Items 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or
related exhibits furnished pursuant to Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus
supplement incorporate by reference the documents set forth below that have previously been filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022002962/tern-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;7, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1831363/000095017022000398/tern-20220119.htm">Form
 <FONT STYLE="white-space:nowrap">8-K</FONT></A> filed with the SEC on January&nbsp;19, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1831363/000119312521014462/d328418d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on January&nbsp;22, 2021, including any amendments or reports filed with the SEC for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All reports and other documents we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this
offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the
filing of such reports and documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or
telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Terns Pharmaceuticals, Inc., </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1065 East Hillsdale Blvd., Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Foster City, California 94404 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +1 (650) <FONT STYLE="white-space:nowrap">525-5535</FONT> Ext.101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fax: +1 (650) <FONT STYLE="white-space:nowrap">275-4254</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>investors@ternspharma.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any
accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_3"></A>ABOUT TERNS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to
address serious diseases, such as NASH and obesity. Our approach is to develop drug candidates based on mechanisms of action that have achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in
clinical trials. Our most advanced drug candidates are under development for the treatment of <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis, or NASH, using clinically-validated and complementary mechanisms of action to drive
meaningful clinical benefits for patients. In our NASH programs, these mechanisms have demonstrated significant improvements on histological and <FONT STYLE="white-space:nowrap">non-invasive</FONT> markers of the disease, though no drug has been
approved for the treatment of NASH in the United States or Europe. In addition, by developing combination therapies, we are aiming to expand the reach of our single-agent drug candidates through improved response rates, better tolerability and
improved compliance as compared to monotherapy regimens. We also have an oral small-molecule glucagon-like <FONT STYLE="white-space:nowrap">peptide-1</FONT> receptor <FONT STYLE="white-space:nowrap">(GLP-1R)</FONT> agonist in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development that may target metabolic diseases such as obesity as well as NASH. Beyond NASH, we plan to explore other indications with high unmet need using our pipeline drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the Cayman Islands on December&nbsp;9, 2016. On December&nbsp;29, 2020, we effected a <FONT
STYLE="white-space:nowrap">de-registration</FONT> under the Cayman Islands Companies Law (2020 Revision) and a domestication under Section&nbsp;388 of the Delaware General Corporation Law (by means of filing a certificate of domestication with the
Secretary of State of Delaware), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware. Our principal executive offices are located at 1065 East Hillsdale Boulevard, Suite 100, Foster City,
California 94404, and our telephone number is (650) <FONT STYLE="white-space:nowrap">525-5535.</FONT><B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully
consider the risk factors included in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and any subsequent Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> we file after the date of this prospectus, and all other information contained or incorporated by reference into this
prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement and any applicable free writing prospectus before acquiring any of such securities.
The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary describes the capital stock of Terns Pharmaceuticals, Inc. (the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148;) and the material provisions of our amended and restated certificate of incorporation, our amended and restated bylaws, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties
and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of
incorporation, amended and restated bylaws and amended and restated investors&#146; rights agreement, copies of which are incorporated by reference as exhibits to the registration statement of which this prospectus is a part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. As of December&nbsp;31, 2021, there were outstanding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25,269,271 shares of our common stock held by approximately 25 stockholders of record; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,577,485&nbsp;shares of our common stock issuable upon exercise of outstanding stock options.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actual number of stockholders is greater than the number of record holders and includes stockholders who are
beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and
restated bylaws are summaries of material terms and provisions and are qualified by reference to our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed with the SEC and are incorporated
by reference as exhibits to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of
common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders
of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66 2/3% of the voting power of all of the then outstanding voting stock is required to take certain actions, including
amending certain provisions of our amended and restated certificate of incorporation, including the provisions relating to amending our amended and restated bylaws, the classified board and director liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences
that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends as may be declared from time to time by our board of directors out of legally available funds. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our
liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the
satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, conversion or subscription or other rights, and there are no redemption or sinking fund
provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we
may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our outstanding shares of common stock are fully paid and nonassessable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and
privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be
greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our
liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of
shares of our common stock, are entitled to certain rights with respect to registration of such shares under the Securities Act of 1933, as amended, (the &#147;Securities Act&#148;). These shares are referred to as registrable securities. The
holders of these registrable securities possess registration rights pursuant to the terms of our amended and restated investors&#146; rights agreement and are described in additional detail below. The registration of shares of our common stock
pursuant to the exercise of the registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the
registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations described below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will terminate upon the
earliest of (i)&nbsp;with respect to each stockholder, such date, on or after the closing of our initial public offering in February 2021, on which all registrable shares held by such stockholder may immediately be sold during any <FONT
STYLE="white-space:nowrap">90-day</FONT> period pursuant to Rule 144 of the Securities Act, or Rule 144, and (ii)&nbsp;the occurrence of a deemed liquidation event, as defined in our amended and restated certificate of incorporation, as currently in
effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock are entitled to certain demand registration rights. Certain investors holding, collectively, 20%
of registrable securities may, on not more than two occasions, request that we register all or a portion of their shares, subject to certain specified exceptions. If any of these holders exercises its demand registration rights, then these holders
will be entitled to register their shares, subject to specified conditions and limitations in the corresponding offering.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that we propose to register any of our securities under the Securities Act, either for our own account or for
the account of other security holders, certain holders of shares of our common stock will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in such registration, subject to specified conditions
and limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">S-3&nbsp;Registration</FONT> Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock are entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights.
Certain investors holding at least 10% of registrable securities may, on not more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within any <FONT STYLE="white-space:nowrap">12-month</FONT> period, request that we register
all or a portion of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> subject to specified exceptions. Such request for
registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> must cover securities with an aggregate offering price which equals or exceeds $1.0&nbsp;million, net of selling expenses. The right to have such shares registered on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of
Delaware Law and Our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of
Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us
by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be
in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly-held Delaware corporation for three years
following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies.
Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting
stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with
respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to effect a change in control of our
company. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Stockholder Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation provides that a special meeting of stockholders may be called at any time by our board of directors but such special meetings may not be called by the stockholders or any other person or persons.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for
election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board; Election and Removal of Directors; Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes, divided as nearly as equal in number as possible. The directors in each class will serve
for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of
their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding are able to elect all of our directors. Our amended and restated
certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on
our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies shall be
filled by the stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more
difficult for stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the
selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our
behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law,
our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); or any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any
action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will
not apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;), as amended, or any other claim for which the federal courts have exclusive jurisdiction; and provided further
that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and
restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action against us or
any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange
Act from bringing such claims in state or federal court, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any action the subject matter of which is within
the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state
and federal courts located within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated
bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation
and amended and restated bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for
disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws
and the rules and regulations thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision making it
possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated
bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile
takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their
best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#147;TERN.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is Computershare, Inc. The transfer agent and registrar&#146;s address is 250 Royall Street, Canton, Massachusetts 02021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the
fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our amended and restated certificate of incorporation and amended and restated bylaws provide that we are required to indemnify our
directors and officers, in each case to the fullest extent permitted by Delaware </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
law. Our amended and restated bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to
secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We
have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for
related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are
necessary to attract and retain qualified persons as directors and officers. We also maintain directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action,
if successful, might benefit us and our stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus, summarizes
certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus.
We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this
prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one
or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a third party to be identified therein, as trustee. We have
summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In
the summary below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this section only, &#147;Terns,&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148; refer to Terns Pharmaceuticals, Inc., unless expressly
stated or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the
manner provided in a resolution of our board of directors, in an officer&#146;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating to
such series (including any pricing supplement or term sheet). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue an unlimited amount of debt securities under the indenture that may be in one
or more series with the same or various maturities, at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being
offered, the aggregate principal amount and the following terms of the debt securities, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and ranking of the debt securities (including the terms of any subordination provisions);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal of the securities of the series is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the
method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may
redeem the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities, which may be United States Dollars or any foreign currency,
and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of, premium and
interest on the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or
currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities
will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture
with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with
respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if
applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including
the terms of subordination, if any, of such guarantees. (Section 2.2) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal amount to be due
and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt
securities in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies
or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the
restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt
security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or the Depositary, or a nominee of the Depositary (we will refer to any debt security represented by a global debt security
as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#147;certificated debt security&#148;) as set forth in the applicable
prospectus supplement. Except as set forth under the heading &#147;Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certificated Debt Securities. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the
terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection
with a transfer or exchange. (Section 2.7) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium
and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of
a new certificate to the new holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will
be deposited with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see &#147;Global Securities.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus
supplement any restrictive covenants applicable to any issue of debt securities. (Article IV) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change of Control
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the
debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) which could adversely affect holders of debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not
consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any person (a &#147;successor person&#148;) unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving corporation or the successor person (if other than Terns) is a corporation organized and
validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its
properties to us. (Section 5.1) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Event of Default&#148; means with respect to any series of debt securities, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the <FONT STYLE="white-space:nowrap">30-day</FONT> period);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any security of that series at its maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a
covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or
Terns and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Terns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other Event of Default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement. (Section 6.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Event of Default with respect to a particular series of debt securities (except as
to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration under the
indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide the
trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what
action we are taking or propose to take in respect thereof. (Section&nbsp;6.1) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to debt securities of any series at
the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders),
declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if
any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all
outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to
debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind
and annul the acceleration if all Events of Default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest, if any, with respect to debt securities of that series, have been cured or waived as
provided in the indenture. (Section 6.2) We refer you to the prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount
securities upon the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture provides that the trustee may refuse to perform any duty or exercise any of its
rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to
certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the
trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No holder of any
debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the
outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the
principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section 6.8) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture.
(Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each Securityholder of the securities of that
series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to
the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice
is in the interest of the holders of those debt securities. (Section 7.5) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with covenants in the indenture described above under the heading &#147;Consolidation, Merger and Sale
of Assets&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated securities in addition to or in place of certificated securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to surrender any of our rights or powers under the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants or events of default for the benefit of the holders of debt securities of any series;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the applicable procedures of the applicable depositary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to
or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act. (Section 9.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also modify and amend the indenture with the consent of the holders of at least a
majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of,
or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission
of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such
acceleration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of or premium or interest on any debt security payable in currency other than that stated in
the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. (Section 9.3) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf
of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of
all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series;
provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.
(Section 6.13) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged
from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the
case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their
terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal, premium and
interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has
been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such
opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal
income tax on the same amounts, in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon
compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#147;Consolidation, Merger and Sale of
Assets&#148; and certain other covenants set forth in the indenture, as well as any additional covenants which may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to
the debt securities of that series (&#147;covenant defeasance&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide
money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments
in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same
times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4) </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal
Liability of Directors, Officers, Employees or Securityholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our past, present or future directors, officers, employees or securityholders,
as such, will have any liability for any of our obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
releases all such liability. This waiver and release is part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities
under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by
the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the
debt securities) irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated
thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated
thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt
securities (by their acceptance of the debt securities) irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that
service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#146;s address set forth in the indenture will be effective service of process for any suit, action or
other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying
of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section
10.10) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants independently or together
with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The
following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of
warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant
agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of warrants will be described in the
prospectus supplement relating to the issue. Those terms may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase
such shares and the price at which such number of shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and
voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common
stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal income tax consequences applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange,
exercise and settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to vote, consent or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders of Terns. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the
exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified
time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and
exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercised, the holder of the warrants will not have any rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive payments of principal,
premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders
of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution or winding up on the common stock or preferred stock, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_9"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each
series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the
unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional
information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize to be
provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit
to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the
following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain U.S. federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_10"></A>GLOBAL SECURITIES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry, Delivery and Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
indicate differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global
securities. The global securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary, or &#147;DTC&#148;, and registered in the name of Cede&nbsp;&amp; Co., the nominee of DTC. Unless and until
it is exchanged for individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by
the depositary or its nominee to a successor depositary or to a nominee of the successor depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;banking organization&#148; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing agency&#148; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants
of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#146; accounts, thereby eliminating the need for physical movement of securities certificates.
&#147;Direct participants&#148; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp;
Clearing Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated
subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules
applicable to DTC and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases of securities under the DTC system must be made by or through
direct participants, which will receive a credit for the securities on DTC&#146;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and
indirect participants&#146; records. Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions,
as well as periodic statements of their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of
participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of
DTC&#146;s partnership nominee, Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee
will not change the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#146;s records reflect only the identity of the direct participants to whose accounts the securities are
credited, which may or may not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the securities are in book-entry form, you will receive payments and may transfer
securities only through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands
in respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct
participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#146;s practice is
to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither DTC
nor Cede&nbsp;&amp; Co. (or such other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the
consenting or voting rights of Cede&nbsp;&amp; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered
owner of such securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and if not otherwise provided in the description of the applicable
securities herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in
writing to the applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede&nbsp;&amp; Co., or such other nominee as may
be requested by an authorized representative of DTC. DTC&#146;s practice is to credit direct participants&#146; accounts upon DTC&#146;s receipt of funds and corresponding detail information from us on the payment date in accordance with their
respective holdings shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered
in &#147;street name.&#148; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend
payments to Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement of payments to direct participants is the responsibility of DTC, and disbursement of payments to
the beneficial owners is the responsibility of direct and indirect participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except under the limited circumstances described below,
purchasers of securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise
any rights under the securities and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions may require that some purchasers of securities take
physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing its services as securities depositary with respect to the securities at any time by giving reasonable notice to
us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be printed and delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, beneficial owners of a particular series of securities generally will not
receive certificates representing their ownership interests in those securities. However, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities
representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or
of our becoming aware of DTC&#146;s ceasing to be so registered, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Event of Default has occurred and is continuing with respect to such series of securities,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any
beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is
expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Euroclear and Clearstream </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so
provided in the applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we refer to as &#147;Clearstream,&#148; or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we
refer to as &#147;Euroclear,&#148; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf
of their respective participants through customers&#146; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#146;
securities accounts in such depositaries&#146; names on DTC&#146;s books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clearstream and Euroclear are securities clearance systems in
Europe. Clearstream and Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their
accounts, thereby eliminating the need for physical movement of certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments, deliveries, transfers, exchanges, notices and
other matters relating to beneficial interests in global securities owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and
other participants in DTC, on the other hand, are also subject to DTC&#146;s rules and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors will be able to make and
receive through Euroclear and Clearstream payments, deliveries, transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems
may not be open for business on days when banks, brokers and other institutions are open for business in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cross-market
transfers between participants in DTC, on the one hand, and participants in Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be,
by their respective U.S. depositaries; however, such cross-market transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and
within the established deadlines (European time) of such system. Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final
settlement on its behalf by delivering or receiving interests in the global securities through DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement.
Participants in Euroclear or Clearstream may not deliver instructions directly to their respective U.S. depositaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to time zone differences, the securities accounts of a participant in Euroclear or
Clearstream purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing
day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in
Euroclear or Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream
following DTC&#146;s settlement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been
obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely
within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are
urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters. In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any
obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear
or their respective participants of these or any other rules or procedures governing their respective operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, &#147;at the market&#148; offerings, negotiated transactions, block
trades or a combination of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of
distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the
securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a dealer is
utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of
resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the
underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the
purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best
efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions
allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of
the Securities Act of 1933, as amended, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to
indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any common stock that we issue and sell will be listed on the Nasdaq Global Select Market, but any other securities may or may not be listed on a
national securities exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include
over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by
making purchases in the open market or by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by
imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to
stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter
into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales
or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and,
if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may
sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent
offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will
be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in transactions with us, or perform services for
us, in the ordinary course of business for which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on
behalf of Terns Pharmaceuticals, Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx303279_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as set forth in their report which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our
financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to $75,000,000 </B></P>
<P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g303279g06c59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Cowen </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;17, 2022 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g303279g04a37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303279g04a37.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[11V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %%J^4A X0DE-! 0      $X< @   @  ' )0  AR<C,Y,#DX.1P"!0 U
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T(%1O=6-A;B M($9O<FT@4RTS(&%N
M9"!!5$TM=C4X0DE-!"4      !#V2[^GGO[\=\PW=,B^-)?G.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@              T@
M A8    & &< ,  T &$ ,P W     0                         !
M          (6    T@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    T@    !29VAT;&]N9P   A8    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -(
M    4F=H=&QO;F<   (6     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      G?     0   '\    R   !@
M2P    G# !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M"  R '\# 2(  A$! Q$!_]T !  (_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQYFFFCTG)?*+[Z6X\S333EJKAPK L%%5UE#F!SU'45.<YN3QP4.9C&$1Y
M',?    \ TTU&+(N/:3DR*D*Q?:S$VF#<+*F,RE6Q5NP6YG(5TQ<EZ'4<]3*
M801?,5V[M'F(I+%YCJ4L][NU@K$N%FN%3;JM, 34TA0NN03'*G6.:)B!RBF2
M2-L>TAU"W[;MCW1;Y+7N"UT=UH9,GP*N)7\-R"HF@D&)::=03X=13R1S1Y/!
MUR<U$9SX7LHW.\G]O]C0>H_75QH-T=]V<E 1$X-8&U)H&;J_>2:M; V0Y  &
M=6 ?Z1A[';4^R&D58J3>%O\ $P GRK;$ 9B!CQ*FB9P,DY+O3/C)]BF Z#J1
MO?[%)&::MV'=5CY$O\BWJ0D*>_AT=R1"2/XL<=9$2/X]62>E5EZI5WQ;,A7L
MFTZQ4*9,8Q4&]DCE&C1^)1$ICP\RF*T+-H=13 #B(D7J!A >2@\M=A+%NS;N
MY(1/9;K25H..4:2A9XR<$++ _":-NHZ.BGW@:ZJ;EV+NS:$YI]PV.NMI!(2:
M6%FI90.[0U47.GF7H?:CD8=#YZU@.D?$#>WQ 0,'+Q_!R\! ? ?[M67+8&!D
M8 ['R^/O'P\]5,CN/\#_ !^?7FS$@G'L5%CJB03F1;)#U]("JY5*@0 Y"'B
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MKZ/V;\G4O]TNJ-/JE>.;S#_8Q$O!4*TE+;E2.=&2,4BI6[U;%C9<4CF*<I%
M25,)#&(<I3<A$I@#D-IV,2ORJP[JM.P^)59SC\^,:I?I'4.UD0YP\M6IQWPQ
MI0<9R,]>G0ZE 'U.UP\.0?YW9Z]@?]IU/_@ ?^>L'YYWGSBHO^&D_?:DO]'F
MWO\ 6U__ !$'_;::V]#;;C?:3P:MQ&!\2O;#(42GT*6<P[JTRK*:FU%+)E&.
MLLD#J1CHZ):+E))2KLC<$V*0I-RI)*&5.0RAMFU5T]QW/15=0(UEDE 81*43
M[73-&N%+,1[*C.2<GK\-9-YMM-:=GW"@I&D:"&$E#*ZN^9*M)&!951>C.< *
M,#59?#3X*^T'=KLLPYG_ "C+9E:WF]FOY9M"IW*!B8 GJSDVY5&.%BP?4V6<
MH":*@61W/:/U^U=F76)V9%"I$F[YN>XVZYU%' E*T40@*F6%F<^+!%*V6$J@
MX9R!TZ  >6JWMK9EHNUFI*^K>L$\QJ XBEB2/[74S1+Q5H'8>R@)]L]<GX:T
M?A?83Q?LZXR.:-K^3:Q&3UDB(ZV-MN5YLZ(NIF+,FS;7*OO8WGV$6E,VO$4E
M(F>R:3'O39]'.(V+7:%?O$'&[?JJ>Y;:I:^&0HCF,UL49PK#)C<,,%RL=0J\
M1DC#8(.!K8VQ14UHWA6VRIC1Y(UF6W3R#VUPJS1$8XJ7FHW8LW#*E2J\ 673
MU^J$/ZR7#D_XLLO[^XHUB[,_]'>_]E'_ '53K,](/\);>_ES?\S1:8/&UV@W
MC&5RI?%$VME7K^5,02U>=Y?"$;D%5W'0ZB3*O9(=,R@ 22<<V[O3KTU4*LE)
M5)Q'*O$2QT5,+J;&U[G%/%+8:_#T]2K+3<OPF]IX <CCD_;(CT(D#A2&9 <K
M>EHFI9HMSVPF*II'C-6$Z%@I CJ< CD%&()US[4+*3A%D81;X*6; W(<6/=-
MG;T*-=5RGA&\7!U!BL#DD6_D\@X@/(,T' >*[1%\5P#-4X%54:]B98A%1.0N
M=NBE]2V]0T@;Q!3U-/$'P!R"13 $CH 2,9'0 Y&HG95;\H[LNE<4\,U='/.4
MSD(SU%(6 /<@'.#WQC/75A>Y"O<*_B/;O[-M=R]%7JF;I\4(2D K=F@M<;/;
M*QK+ELL:LQ=@>N):*NI5&DN:;@6TI75I$L(1^[B7#5N1=)2(HFO]DML=PIC!
M-05/%Q$>50L9D'21D4*8CE KE7X\\!LGJ;%<8]K[CN\MKJTG@NE*'C,ZE:8R
MK$?O2R%G2?(<R1AXB_AABA49!J+WQ;9Z#PB=U>TW(6RK,5UDKO9IMPK/XUL-
MDBY^>-%L)NOLB,I$:W%0?>Z=D)O)R%?7AIABJNX=,'#B,<JF2$(ZQ6NNFW';
M[A#=*:)88E'":.-D0DI(V5$C.%D@XJX="!A@&&0.52OEMI]I76U5%EJYGJ'<
MEZ:21))."/&O%O#6,&*HYM&4=<D@\.6#P[UZ>835N,,8HD$Q'!A*/M*(NW B
M4?R@(\A^;7%VN:1VZ_H]WPZ>[MI.._LIQ^>4_7'36NL?331IIHTTTO<N?<IR
M=^CVZ?NW):G=K_2;;OY=M'[0I]5K>?T/W9_1J^_LNJUSL;)L6#E;<-2(]TV!
MS!558;Q8B*% Z!F%=4069MER&#I42?32L6Q53'GUH.%>8=)1UWD]+6X_FWLB
M\3QR>'67)3:*$C',35P9)74YRIAI!4S*WD\:XZG7FUZ#=IG=WI'L5-+%XM!:
MI&OMR##,?JUM*20QR#!!2IKFI*9U(ZI*WD#CIIUY_:]2M&FFC334+=^VS*!W
MWX$5P/8[Q+X]C5;C7+>-AA(EG-/2KUTLB5)D#)\Y:("DY](&%145>M/LB])#
M=0\I2T7-[36>MQQ+,PB>/@S%1A\=<@$Y&/=V)U#7VSI?* T,D[4ZF:.;Q$0.
MP,?+ PQ Z\N_7MVT\MON(F6 <'8EPC&S3JQQ^)\?U:@,IY\U18O)AM5XAK$H
MR+IF@JL@V7=D; LJ@DJHFF<XE*<P  ZQ*RI-95U-4RA#4323% 20AD8MQ!."
M0,X&1VUFVZC6WT-)0JYD6DIXH!(PPSB-0O(@$@$XR0#@>734).)!PS*GQ&&V
M)6UHRK8\9!BAQ<'#(]?KT;.FES6].NIK Y](/F7=>X^KR1D11%051<GZ^GLR
M]4I8[W)934F.!)_61'GF_ +X?/&.ASGG[^F.QSTA=Q[:BW"*0254E-ZJ9N/"
M-7#^,(P>7(C''PQC'?)STZ&L3_)H,<?C?96_]$07\1:G_GO-^+Z?_>C_ *=5
MC_1M3_C:I_W$7_5JTRL\-ZM5SAX37#X_E5LDC79J*LD4MDUU!L L*1+'D!Q?
ME%@A0?G8J':+N/1B13/@ [<A5C"4_P!;" >^2/>DO'JZ*Z,A$ <\#PA\'[K!
M[CVN@P#T'3KJT1;<BCV\^W_6I6C=9%-2442?;*DU&>&<>R2$'7[D C';4A]F
M&V"(V:[;<=[<8*UR5WBL>FM@M;/+1S6)D)+UKNMBNBP.&#-PZ;(=S<6%5BEV
M:Y^U1;)K'Z3J&*7"NE>USKIJUXUB:;P_M:DLJ^'$D0P3U.0@/PS@=-2-FMB6
M>W4]N25IE@,I$CJ%9O%FDF.5!(&#(5'7L-1DW,<,JJ[@-W^$]Z$#E:P8IR?A
MLM4)W>$K<9-1MR+4+$]FX\LZ=S(1[D@.H^3?UJ2%(RAG<&HBUZDP;E V=0WR
M2DMU5;'IXZB"IYX+R,AC\1%5N. 0>JJZ]L,#W+$ZC+EMF*ON]%>4JI:6IH_!
MZ1QHZS>#(SKXG(J>JDQ,1[31D@GH-9^^[AKU3?1D/;_D&PY1L./W6 I.2DXV
M-AJ_&S+>Q*2$Y6)LR3Y=\^:J,BI*5E) ID"*B8CM0X\C)% VEHOCVF&LA2!)
MO7%52S,5*<4D48P"#GQ,]1TQT[ZUOVVHK[44%1)524YH&9E5$5O$Y20R$$L1
MQP80.F<ACG5C<Y"0]FA9:N6&,934#/1CZ&FX>2;I.XZ5B9-LJRD8Y^T7*=%R
MS>M%EFSE!4ADU45#IG*)3"&H1&9'5T)5T8,K*<,K*<@J?(@]CJQR1I*CQR*K
MQR*R.C %65@0RL#T(()!&JG]CW"'Q5L2W&9$SQC7)ELG(VZU.STN*Q].Q$<5
MG58*P6RO6=J@A84'1W\J>')76T4@J[9HJ.FZIEW!NW*(GL-UW%/=:&"DG@C1
MHI$E>9&.9'C1T)*8PO(N6P" #T ([56R;2I;'<:BNIJF619HI84@D1 (DDEC
ME \1<%RGAA02!D=6R=&_/@W[<M]%X0RW)3]LQ%EX6+*-FKG1T8EVUMS.,0*T
MBU;5 R3<"/Y:+9)(1[&:8R,9(>C6S5@]4?-6,<FS6C<U=:8C3*L=13$DK'+D
M-$6.6\.0'HK')*L& )8C&3I?=GVZ^3>MM)+259"J\L(1EF51A#+&X(9T& LB
MLK%0JMR"KA2;1> QMHVR99K^:;5>[SG:Y4R0;3-*96]G#PU4@IYBH1:-L#F%
MCP>NYJ8AUTR.8@S^7&,9.R)O!C%GC=HNVR;ENVNKJ9Z2.**DBD4I*8R6D="?
M:0,0 BL.C<1EAD<L$@XEIV);;;5QUDL\];-"RO"LH2.))%^YD*)DNZ'VDY-Q
M5@#Q)52.CRI?:]'?,Z_;7.JGJ\:33O[*<?GE/UQTTUCZ::---&FFE[ES[E.3
MOT>W3]VY+4[M?Z3;=_+MH_:%/JM;S^A^[/Z-7W]EU6J_.%]BH*_C2S95D6HI
MR-\E?0\(JH4.H*S7#F2561-[2IOYU1^DL7_?]$-C^SD(\U_9#;C]=O\ 0;<A
MD#06:G-55JOXPKP&17\BT-$L+(1V]:D4]<ZZZ_8J;2^3]LW7=U1%QJ+_ %GJ
M-"[ 9^2[8S+(Z'N%J+B\\;CJ#ZC$=6BZZ[Z[7Z---&FFC331IIJ"C++VX\II
MBP&J4?)5,V4C4>!079PT4_E@0S>]H_=XA9"Q/W:<>K4&:JCZ;M,3!BWF03=Q
MR3V(4!<_QEAW\B!V'4'I[_J/U].W9K#A=S&3UK!BU"3IZI:^XD9=EF!\VKLF
M[0K2ECOMII6/T$YAH8\9'#%*0L>]GUW(K)2$=))/6PH$,4P?6>N,'Z\=O\?#
M\V=-+9MNAW"QU;;3LU QYET_Y/+.YAW-440EYBF2,;>9^YN:X2*E7[-PP-&5
MAK%12SU5K88VQF6;RT2FW=1QU_G+X[=<^[_SY?UY]_=K9:QNGS"9GCES9Z>(
M]%@GG^8E(RI3:[:LTMW=UZ;6$TW*!UT8YY'(EDK!*OG@J$>,JRX101(I)(#I
MR/3H?//LG\V.WU>?QTUZ<UN*R6TJLY,-[%7265O/0;"9I)J'*LE\;(/LE&JR
MJ$M9Y24+!KKGKH=]Z9<&BZZ@#8&90KX@F5DC ZYZ$],]R<YQY=.F/\FMIC\\
MWIY-UNHDDX=>9MDCBP(-PWA4WYW\!8$[62^S3,8UVK%OF];<PS8CARV<=TCQ
M3$KDW2\2,.OM #WD@$_7]7Z/\]->0_S1FZNUMI)N745.NG[[,C)POZCO$$("
M.Q[E*"H;*QKL(V24=/V[6N.I:Y/V9%$1>D:&0:J%;)]J;0EAUZ=3TSY?7YCI
MDGOVTUESNY"W02E"+ ."9,@$):6F\DW2#QW96# N.F]J1JC-PS("[IHW>)=M
M,S9[ U56@Y5K37B,>FGZ40Y,G Q[77J<'^T=/T9TU\V7<I9"8G)+0<_4VN0H
M[(=F@;1'O8]T!HVN,;+=V$$*1')BPL5)2,="P:C5[9Y&-A9/M5VJ#]M)RD40
M=<_7G/N/;./_ #^;/;IIJ8-#GG5HI%/LKY!=J]GZQ!3+QLZC589P@ZDHQL\<
M)+1"[R06C%"*K'*9@H_?':"'8&>.1)VQ_K34F:E]KT=\SK]M<Z::33O[*<?G
ME/UQTTUCZ::---&FFM/R%$O9Z@7B#C4P6D9FGV:)8)"8I 5>R,*]9M4Q.80*
M0#KK)E$QA I>?,1  $=2ECJ8:*]V>LJ&X4])=+?4SMC/&&"KAEE; [X1&.//
MMJ$W+1U%QVYN"WTB>)55UDNU'31\@G.HJ:"H@@3D<!>4KJO(D 9R2!UU^&-J
M/&XUH%/H40 =PJ=?C85)0"@47*K1N0CMZH   =L_=BN]7$ #J674-R#GK[O]
MXJ+_ 'JZ7JJ)\:YUU15LI.?#65R8H5/?A!$$A0$G"H!G7QM>P4NUMNV7;U&!
MZO9[=34*L!@RO#&!-4-CIXE3.9)Y#YO(Q[8UN^HC4]HTTT:::---&FFC331I
MIHTTT:::.0?@_+_X_A_^ _NTTT?]?]?W!IIHTTT>SV:::---&FFG;4OM>COF
M=?MKG336.K6H0RBAC,2B8QS"(]NY\1$PB(_[;337QZL07N!?CNO/TTT>K$%[
M@7X[KS]--'JQ!>X%^.Z\_331ZL07N!?CNO/TTT>K$%[@7X[KS]--'JQ!>X%^
M.Z\_331ZL07N!?CNO/TTT>K$%[@7X[KS]--'JQ!>X%^.Z\_331ZL07N!?CNO
M/TTT>K$%[@7X[KS]--'JQ!>X%^.Z\_331ZL07N!?CNO/TTT>K$%[@7X[KS]-
M-'JQ!>X%^.Z\_331ZL07N!?CNO/TTT>K$%[@7X[KS]--'JQ!>X%^.Z\_331Z
ML07N!?CNO/TTT>K$%[@7X[KS]--;A%L&C5@@@@CV:2?:]! .H;EU+*'-XF.8
0P\S&$?$1Y<^0>'(---?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g303279g05b43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303279g05b43.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &'Z^8G X0DE-! 0      $X< @   @  ' )0  AR<C,Y,#DX.1P"!0 U
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T(%1O=6-A;B M($9O<FT@4RTS(&%N
M9"!!5$TM=C4X0DE-!"4      !#V2[^GGO[\=\PW=,B^-)?G.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0%>A1\         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@              _P
M E0    & &< ,  U &( -  S     0                         !
M          )4    _P                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    _P    !29VAT;&]N9P   E0    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /\
M    4F=H=&QO;F<   )4     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    '.$))300,      X#     0   )\   !$   !X
M?X    WG !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M<-S-OM58?7?HP=)ZGD.$$ '%=R1#7>VMOT%C?\S.B_\ SPT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@;[&W>6'G7A$HQ<E9 "A6U07WMRI\$9>RY(>25)<CD<N$AM2@01D'*9*OA!
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MSU%Z*N4TRMO?1B4(3E8.2[7#$U:P>CZ,'XQPINSILZ;,F E(*2D &I.4@5N
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M$5QED8.AB5A;LU&9@PI3C7Z.]8[FSY<R62%A0)*C^(*U-1J+C72UP.Y:3<U
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M>Q&?8CV3<-PT"J3W'([<FGQF*A*M6KSZ$'YK,NL066Y4.(XL%I!K5-.)]+/
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M)=)2578NE##FZQNIY\83X93P6AZO^S*5)4% (_6]>!PG#+JE .Y2>K)!X.?
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MY\R>F.RR>TLESKEO4&F>Y%"WC ?#+># )PJK-+"T(0I0V[E$)P7 C@)EE2<
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M^-AJ_H=\;!H5)_F IN\QRW7\+AY.63PY\A;4)R1_Y*:'"0<8/+&>X\^\8(T
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MT9K*VJ7*;D!Y.5I3G^X3S5_Y\H8LU^%[CG3A'+.W,!+4J2XSB7UJNR^YW?4
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M0\A'/.-=G8> &)GI2L%0=[FH??Y'PI'DNE6U5;.P!$LY5K=(+.0Z740[&H+
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M^57^:#B![U _#HR?R$<DMZ-$'K#HL<E$09'K'QC1D_D5X'WB,LPW2L\2JWE
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M63&>(9+;J5'#(VJ5+4E<LD!F(2U&'TH>=[0Q6SQ*$K),20HJ#%1)8 Y;T!+
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MW3KHE5>+&5-NIM5%IM*0_-6^E*9#LRJN5+L[76-*8A.,(<4E*R'7A.8ID9@
MQ[+E)&M78GN:*)E3!)2HS4JFJ((&A14EDAV2P )-3?EED;H1T>;-@1;JWC13
MKCKJZJ\U'G183[Y:HT/M:U3Y#M04XF94F@VS3F'./C?(;4H( (E&)6N\@]HO
M^$4.EP6<@W%:;Z6*.R2A,MD"K+T5P:K5%]6NSZZL+8:Q1N3NA0;F==NS;RPH
M-.55KTASQ2TT1,]4(+4W3HZG':U74/RS B4V%QQUS&R\Z\W'0I24Z8K,D"44
M'*WX0Y-]UPQ>HJ!W60@JEYC,3*459B"Q<.UR R22'H]8W),Z.&R%%BRZC4[?
MK4Z@VM%JSEPUIJYVS,?M:-'M1RG7M%H\<NR7ZG<52JU9H=M42"'6'U1#/E.L
MQXKJDUZR<H,$T31V)<:G>]RXX'=&1*)#A7W@58J T421E>V4442X/>6'&N[E
MGV):5'VA8M%51EU.Z-M$WA>K]2=CJ+=9K%S7'3H4"+&C./-0XS%(H\22$J6)
M#JIQ6ZVWY@.7"A:EJ"P"**M4@N1N -Q3=O$:T]2<RE2YCA*RAC4)6DG-_P R
M6((<.*BP!.GFFS@#B* 5$J)P.:4 +4>Y*4!ML)4KT>;WZVU=A3D4%FL/"]6L
M.="\:4R8"Q;,19J:TIJ22*.]"-([D\&KM!<N]/3AZ/%NVY%D2&K8W&M_<>XY
M\=MQ3-'MNPY\:XY4N8Z$]6TU*D1(--9*U)+KTY ;!.<<7;./D2\,M)*<Q2NI
M8U  %QJ57X<(])T:P2L3M##*ZM0 6DK8&SE146);*$J-6J 'JX_0DJY95'CJ
M=$AU/C&GK2(^0MMQ<D%M!Q@JC-I45.*/+@40>X$_(<RE3UJ#,57',DB]='_M
M'Z)PLL2Q*60:.&W, +-2E_@BXJP.+D,@^>H# *L9.![G[;_"R/1J2H!=[,..
M[G<^G"-F8RIJE@&H(O1AKI8@^D,!SS]'H_K[^=9@7J(I"Z0AB^X>_P#H.J+L
M.?T,(BUBA!I"#5$W7S^IA!J\(-(115$(,"87$N*;$9_C2R#UIRTO'58Y];WA
M '>3JR:O2A9]]]/UNS7:$.@A B10D. =EC\(=&'0CJD?LF>?6=W$#S"@?7K'
M-2$V>^IWO8:5\;PB5_V _?#YCJB+GE]1"*766$&D(-(0:0@TA!I"#2$/;_9&
M_P!^G^4-63_-_P I^D(WT!EAG)('"GNQDY3R&#ZSRY:H=UWIW:]T/I' 72JZ
M'2^DQN9MG<=6NF91+3L"U;TBR*;2)4F%4JO<58K5CU.AK,Z.M!@T^([;<DSY
M$<*E/M.&%@1Y4@ZZ>$Q2,.FR22&((#C>U0'W/'"VILU6T"P4I+.^4D:V8#5[
MTL-T<J47H2=,VR:'LK9^WG2);I-J;>77M=6KBC3JM694Q^D42SK HU^VO3'.
MP*;5;%;JM NEZB4Q]8%-9KK7"K#2BC9&-PF8KF("BI[6<DD4&K4/&IW#DG9.
MTAU<K#SNKER@DI<DD'* 25/49J\0 V\YQL_T6>F]9^Z^S-TWWTD1<&WMF1+Q
M8O.SH\ZHS':YXUK%X5&G.SYLR$SX[<+%6MME;SQ8,$T!"(H<:6KBK-Q6#4@A
M,LI%*G4LP?5ZU\>>7#[-VI+GRRO$%0%"ES0."::YF(>OXK!J89<W0OZ6\BJ;
MGU[;6_;&VFNC<+?FAWX_6+;KET*CO6+0!V&F41=+?AO1FJL_ ;:D7%)&/',N
M?)<=)#+0U5.,PX204Y@4'*& KV')W@L6#4=W+Q8[,Q_6+6F9DS30HC,2,K%@
M 0S@ER;N;,(Z"WEZ'%TW]NXC=*TKEI=I5V99%@6G5[DIST^!<RWJ!><NK75*
M@S66W6F'JQ;3D2B-O%KKBTR&EJ2VD$XI&-ERPK-+=W;L@UXOH_>1SC+C=C8F
M=.DS)4U*0".L8D*4#4L7#%MS58@$@-S?5^@CTNZC4Z+07-\Z$O;"';B:=5[:
MD2:TX*U/1=U,N&-,GL*AA"I4=N"L)F!P*=<<"5)"01K>_:&%*"4RF6 *Y7#@
M:"CZ,7'+?HJV)M&7/0)6) DL20HN0=S@N/!G?>T;&WSZ$6\6XNY>X%Y61=]*
MM*G7/;UL,E<:Y;GCUBMUZUI33T!+DN-'S:],;:2ZW-8I:I#%42I*GVDK3C5)
M6T\-+&69+#DFH <7()%+.0=7I6\9L3L3'32%RL2I-!99!5H1<,[&M1:D8W;?
M0MZ8-7;NJE;I=(V=+MJLU^]:K2:+:MPW##<@Q*S;%9IUMTURJ+A,S'85.K<N
MDSY$=)25=@6\VH%00;3<?@U(>7*2)C!B0Z36M*"H/ZQ3#[*VBDE.(Q$PHJR<
MQ#?EJ""IBU:$LQH[>E^PMF7!MYM#MO8UW3$U.XK5LR@T&MU)-1F55,^ITFG-
MQ)DY-1GI1-EF8\P9"G9* L*7P95@$\2<1,)-')>C 6X7N?.E8]1A):I*$@FP
M:I<O5Z^O=?3<K2,)2<<_.)SG(SGF/?&,ZP#,%!)--*#01M&[[[P1_N=C^!:_
MD)UD5<\SZQ";#D/2&I^ZW?\ %V/]9(U$3%1I" \OZ-(1!YBP2K(SD8*1Z#R.
M"%<_1[H]?>4(0--(!*<@^C!/+E@\@/5Z"".?+&=(1S+TL$7"K:.2F@BH]E7=
MUEHND4GKQ/\ (IRX8:+I$?LZ1)2#3%.APQ^)_J^()(',(1Y:1NC;TX+,HT6S
M[&B3*G3KLH^_JZ/<5=OM?'M5=^Z^X\NG(CU9Q,B7.G6C$M&I-WO:CE-CU&90
M9$2;20AL28+*88BE:,*WI?VL#>%Z[XCD]&3I04.G[;VS4[#KUTUO9V34MO=N
MZI%OA=Q;;5:Q(]\4J[[,J%7J,NXK8O>TJ_;ENJA6D_?DBDUR0^+;J"7*(^R[
M';J)M_\ ?](1=*_T?^E!8ELQ;RNB\+JKE.I%A=/$4RU8+C0EVCN!NMO/1;EZ
M.J8D^FUJ7*N:;4YAIBJ,5P4HH:5+AR40FEO-)?/[5I MY#TK'MA3&IIIM/-0
M0GMY@P^V]5R95)5&:,DME*B"A;A<21W)ROA\XEQ4PII2+D4+P1U8P<>@\@GV
M('/'F\L$Y5R S@ :0B%Q"L\PH$Y/)*E=YYG(SWGUGWM(1$1PYR%8P.]*D^GW
M1^<:BYR[P_J/;ZF("RA8+ CY\W^D6*Y+?HEV4.J6Y<=*A5FAUR#)I-6I=1C)
ME0I]/FM*8?C28RT+0\P\E90[Q@!.<@@\]9)<\R9B5))!!!!T?Q%FKH6C%/P\
MO%RUI6A*@H%)!#/OO2N^X\H^<#I#> "J54<NN'T4]^7-K; O6NMW'6=I[PCS
MY5 9JT1B?$871JY1FG*HW%;C52?"1"<C\/8'W(K\B4VHI3ZW!=*94@)1/D]9
M,9BH"F2C7+N[TU!%A2/G>T>@\^=-6O"SI<M!327,!<*<DD !E4HDD @<Z\BG
M]3J],)MIZ*.DQMJAB3$9@OLIJ>XR6'83,1Z$Q#>CII74.Q8T27)A,17$N1VH
MDB3%0T&9#[;G33TLP.9QAG) +E)<5<"C!J4HU(XZ>@6U4N/O$I*2[D$AR;FU
MR;EA6MV,1N?J=7I?NO"0[TEML5R1/CU9$I=1W%7);JT..(<&K-2%4DNHJD"*
M!&@U%*Q,AQ_L,=YIKS-3-Z48&80>J6.RS @"@+$@O5FJ+BE;1".@VUY:AU<^
M7E%BY&K_ ,H +EB0*$UT,;<W+\";X1O=YRD*W)Z9UC7,:);SUK4\.3;Y@)1;
MTLH,VDR/%-OP1.B3BVCMC,TR$O\  .,'&L'[Q;/)?)-O^9(<[[/NJ[#QC*OH
M5M?\(G2S0-4V!+-N9R06>M26#:L:_4\?3%CN!V/TGMO8SB7"^E<:L[E,%+Y2
M$=>%(IB5!\A"!UI*E#@3PGS$XS?O1@DI4D2BH$W-2*-0NUG9P6/=&#]Q=M.#
MUTH BKDAPYT9]::EGK%T1^I_NFRS;5>M!'2GVV7;5T.0'J]1Y,V_IT2HN4V5
M)FPU.(F4.06^KERY,ESJ.I[2^X7I/7.!*DI72C!)?_#DN02X#4X@GAH"-(3.
M@FTU93-GRW#E/:*;@@Z5W!_2,(/ZFYZ3?+_[=MEC@8 $>]@ !W ?V!'N^C^C
M:5TNP89I1 9JAZCN.C?*G6_V>[1-4SI9WU>O</K^K3^IN^DX.[?/98__ (>]
M3_\ L!^?6/\ >["FR .8;ZCT[]T_[/=IC^>4>:B/1)A/_%O.DYCGOGLN,D!)
M[->F.(]P.:!R!]?/'Q:?O;AO_2*N6GB?;A6D2/L\VF?YY0T_$HN3;^4>?C6E
M.W^IQNDL\_+C-[Z[+*?@ACM2!'O3#?: X6L*\0 'B#2R1W@#GWZD=+<*;RE)
MO<N[:B@IO-N)B/\ 9YM2K+DEMY4-1O%J_*M./U-[TG#S.^FRR?5]K7HKW^Z@
M*'+EJ/WLPQM+4>3<+O#_ &>;2_GFRD[LJU5WO32GC#3^IO\ I. X&^>RRAZ^
MS7J/@QY/_P!<ZG]Z\-^10\/H#$?[.]H?^XE_YE'Z"$/ZF_Z3O_KQV8^"/>9^
M>@#3]Z\+JA?< ?I#_9WM#_UY9XYU#Z&$/ZG Z3W_ *\ME_A8O$?/0-/WLPGY
M9G^7](D?9WM _P#'E_\ ^P_4"#_Q<'I.#OWRV7^0O$_-01J/WMP@_D4>8(]!
M _9WCQ_QY?\ G)]!!_XN%TF__7CLO^3WG_V%J?WMPAM+4>Y7M$'[/,>/^/+[
MUJ'_ -3 ?U.%TG,8_7PV7(S[7O+(]7?0N?Z,:C][<.X9$P!JL6'?F'HU(#[/
M<=_ZTDG1YBB:[NSP^AO U^IQNE"PZA]G?39QEYI25-/,IO5EUI:2"%MNM4-#
MC:QS\Y"@0"<$<L65TLPRDY1G9W?5^8-/",@^S_'IIUTGD2:\PU?[\8<O]3F=
M*-96MW?K:!Q3F0Z7%7PLNA0=2KK5&BE3G$'7 5+/%EQ1!XE%6L:>E.#2^9,P
M[O,$6KIW5UKD/0#:99ITH!C8VLS7W;@Q#1 K]3L])YB7$A)Z0&T:9?!)JD1M
M*[X2GBAJALS)2%)HR$M2E)D1D.2$A,EQ./LI"!PV'2O9[?[N86-*^KC4/:M(
MH?L_VL_^]E&A=E:49(<:: T:)$_J<[I3)>0^G?S:8.H5UJ'>.]TN]8'7' ZE
MU%'ZP'C<6OC2I*N-2SDE:\XU]+L"D)/43%U)!9V&C,1R+-5VXRGH!M4DO,E)
M8LSTL'#-P#N 6RTAS7ZG/Z4[2F5-;^[2-*BJ6N,6W+Y;5'4[Q=<6"W1@65/<
M2NM4WP+<XCQJ4>8LGIE@6'^%F C4ZOP>G$'4F+JZ ;5(K/E,= 7Y:%FXB\,'
MZG+Z4*$J0G??9X(<<0XM \N EQY!RAYP>(_/=1E12M9)3D\."<Z?O?@B"!(6
MGNO_ &TU[ZQ3_9_M,5,]',O;<^4,-?TB17ZG0Z5*GD/_ *_NT?7(45AXKOI3
MH5RPI+JJ*7$N)_:K"@H#EGD,51TMP*?^%-I:YOSK2P L(C]P=IE\T^3W$]^G
M+X\*C]3I=*1KK2UOWM$RI\$20TN^&1)!/%B0&J*@/Y4.(];Q%2B2LJSDYCTP
MPB_^"MAJ4F_CZ:WX5'0#:0)/6RCN<V[FH^K=P&B)_4ZO2J25<'2!VH27&4QU
M\#U](XV4@I2TH)HR06DI4I*6B.J2%JP@$YU!Z686W5$:&BC2O!N6G"+#H%M*
MKS)%W"=.ZAKO)O2(3^IR>DY@<>^&S2B"D():O$D)2D)2@9H1(0@>Q0,I2,\(
M&3JG[WR$+!1*(?0I>S,+NVYG/+7&?L^VB;S)3%W91%3<T %=:%]8N=&_4X72
M ?J<--Q;][64^BE\>,95'I=U5*I-QE!:7C$A2:7"8D/G*>K9<DLH6KO<0!G5
MY_3*2J4?X1SM3*DW+;RU+-IXB,LG[/,6E:3-FRD@LQS.>S5Z)-22!46)WN/?
MSH.^#TV9Z"EG3J+8$29<M\W$B,J]=RZ]'93<-=<CDJ9IL5IA*FZ/0HBR'XU+
M9>=<ZU95+?>"&DH\5M/:\_'*8(R(254J"<Q''<&;3B8^C;$Z-8;94L32H+64
MI!(8A)2[T9PYJ27<C^6T=LU@.(8CJ6Z_#*ZE!3UB&%K+Q7)3]JD <DR!]AX\
M80"!Z<ZY2"4@YAN:]R3>]2]^>ACT*U9D*R4RU>PKR8!F-3^ANKC#X!!CJ3YQ
M"DA*C@]Y'%CGG/'GN/%RQC4$ DD."6?=2KL2W!Z\KB+(+H"C6X8ZN.YO+F\0
M!EX<PT[S]!;6>?Q#W/?^#EE!"0#6NGJ?AW0IN-SK^E3OA2V_Z&7?A:6/IT*R
M?PA][CV,"VC]Y?Z"&EJ0KEU+GK_8U#YQJJE%@X;N/ZQ$)V=_\"Y^(?HU1QQ\
M#[0@[.]Z6G!_D'^C4%3!P">XBG>(D $L2W'XT,++X_N3GXA/S$8^'4R\G:)+
MNQL0U]SQ+;R.X@^I$)U3_P""<^3/UM9?X?S-#*-__P ?^Z#JG_P3GR9^MI_#
M^9H91O\ _C_W123VG1!EK67HZ41W29"6EJ,=7 KAD! XBM36"I*<<SRU(**L
MW%W9GXW.Z(( X^'T)^GL^&TZJ+&6D.R..,P1(+*TJD M(R\I"@"V7%944\^:
ML]VJ3 %-74V/AO:];5B(E<COD *:= SG]CQS_P HZHE(!U]?:)9]W>6]8B[*
MO\&\/\@?H)U:F\^ ]X$-N\0?2%[*O[QW\32F\^ ]XB#LJ_O'?Q-*;SX#WA!V
M5?WCOXFE-Y\![P@,5W]JT\H^H(R??Y9U!8:^( ^IA$18=!P&'\CORVK'O<AG
M/YM(0G4/_@7?DU_1I"'M1WRXWAE['6(R0TL@#B'?RY#W?7RU;_E>S$D>SL_P
MQ%=6\7^@C>0/$TR"DJ"4@]Q&% )[_CSCW-4("@Q>[TB84,H/,\LCF!E))/?Q
M9'"3RY^;S.3Z=0$@.'->/R_CNBJE,'OI7E](8I*4@I0,<2@"/002HG)"?VP4
M4D#T'ECOU)(%]_ZOW-$@E0!L=]FT\.>X1Y7]+'<7>VV+]Z1*-L*M>+-Q6OT>
M=BJWM;;ML6Y,O!=9J]?W4W:C7S-BV_!0J0Y.?C4&U:+-?3Q^*Z:J.KJ29R7!
MU,*C#K2D3,M3VB68"C, '))&_>[1Y_:$W%HGJ$@J<)>6D#-FK4%1(8)U.X@7
M,&U>X/3,K&^U CWA;4B+LG4+UWQX*@_2*K%N$6]3VK6<V_17(,B"U$I5/*I-
M731)0GO3*F$2!(CQU0\JS3I.$0A/5J25]DL&U=V- 7H#0T:E0VC@L3M29-G&
M<A75"9,R*RD'* ,@*22:!BEV=1(IE<\UQMW^G).JS<FB*W<=MV5NQ6?)^)7]
MH*G'N)FE1ZQ;46-;]Z@):BLVO/MYZZ+@I52@+/4)CT^E39J9T=U#N9,O!%"0
M1VRS]L -5V#7=Q5FC77B]J!2\B)B@ K(Z%.5!LH)=@G*":.>+F+A#WEZ6\VF
MT0+J&]-.\;;]U!AA^X-GJVR*!M9&C-IGM7^[%C (C2EEQRVGJ2E74!69[_VN
MX2",*%T# I)#JN:,'-"!J[$MQ,8!C]I&4#-$Q'\4))3+((0Y?,7+Y@"R4NVM
M8]->A[<ESW5L5:M5NV7.G5)Z;=+3%4J16J?4Z7$NBKQZ7,D+6EOB*X;3*$*X
M$A3;;> >:CQ\7DZPJ2'#L +5T]J'<]A'K=FS%S)"<^:Q(S.Y + E]?UW1U!U
M2$I*4\12<Y(*CGB.3S.">9(]ERSCG@8U?Y:!N#L16KD\-^D='G4;OFZ'H:;!
M2OSB2,9*P1Z ?-QW\AG [P#Z]$Y@:LU?@;>=\02!5O#]?J8JN-.0!WG/H/H&
M=7A7@WSY\I''^YV/X%K^0G4JN>9]8)L.0](:G[K=_P 78_UDC41,5&D(8XE2
MDX0KA/K_ *@Z0BWJBR2HGM;@SSY()'QA)&D(<(LDIP)CO/.04@#W^:<_-[AT
MA$1CN#S7):SR(4E3"5A0YXR5#. >8 P,CGD=Z$-$<@ "8Z,=WV 8& !R23PC
MD ,!(&!W<U90A"P<\YK@]C@".VD)X%<2,8 5YBN:<D@<QCSE90AJV4*P%RRH
M@I4DJC-DIX5*6.'D0@EPAQ2D@+*VVSQ )P4(480 E-0<0!W ,I'+)^$^^HE1
M]))TA"\1_=)WY(?3I"#K>'_G)SGZV$GYP=(0Q3H41]O+6<<CU"1CW.0 ^$Z4
M2ZJTHX/J._AK6\07)"0+N26<AAIIOXVX1$I8SYLU?$D$XZMM*B!WI!('&">]
M(Y\O<(-5(*@E1+!ZJ8L1S\+N 36)!=80"W].H-KT _RV!W122*A%BM\;U3;:
M2$Y*G#';!4<\E(!  )R,J3@G'G9QK+*E3)I:6G-R!#/:P/P6WZ\_$29.8S)R
M4%)J%K#T&MAPWT-+F+9Y545",^/(@PKAX0Y%X1SR0//5RR<@C"?4,]^R,%B7
M82RX - K7N^>,:LS:^SR@'K4((+$]8DAV&A4=]*Z\(G%TT7AR*_&!/K7$/+U
MGSN\^^#W:J,%B7(,I3#5E#U1%OVI@2!EG2QV1_.GC6YY-:D(;FHA4";@CX">
MXKB=_/W?1_W:?<\2Q:4HG,:EQ0#_ )1>]M_**_M/!9G.)0&%LZ._6UOEE3<]
M$P?[8(HS_P"\B\_Q<^G/O9U;[EB/_24>3MYI>).U<%IB)3:?Q$N/,ZN=W"'>
M4U"/?<,7\>-\^ =0<'B=)2@-14OY0&T\!=4^4=SK21Y*2/+]$-S4(=U?BGW>
MLC?ISJOW3$"\I7>%?2!VG@C^&?+&]EH]U?2&&Z*$GOK\;G_AQC\R3JPPD\_\
M)N;CU4(?M+"?^X1_G1[0WRHH*LXN"(,)[U*C=^1R&>')[_01[HT.#Q#AI2R#
M^49O%LQMQ'@#%3M/!:XJ6DM1YB*^!'C%NBW)343JBIRO4A4=P1"QU!B]IRE+
MW6]L&2.1*.H[CCK,G16#Q-'E3 + J!#[V!&FM](A.T\(2IL5*4S. M!RN[/V
MBS]UJ1<S<U"[Q78N.>0%1/@[QGXLZC[GB3:43QK\_O%QM/!)_%/0><Q/N(:;
MHM[TUV-W?]4/+X,ZG[CBO_2))LQIRJ 08M^UMG@5G2^><>F:W%VXPU-U4(YX
M*ZPD9QR,< GUX21Z,=_/4?<<6'>2K@Q%N\CYI$#:VSE!Q,ED"Y))8ZV4 //G
M#O*V@IY*K[&3S'V1D<O>SZ_3R]6I& Q9_P"$?$-WDBD0=L;-!83$5T2H>?:^
M-PA4W70E9_L^P,'[YH_[8^;4'!8E-Y9KQ!]'\XE.UL"IR)J!S5_^0?GY"%-U
M4/T5]D^\ID?.3H,'//\ (1X?4B"MJ8$7FRN]0_[C#5770P"?'S'IY%QG)/N
M YQZ>8]'?SP."Q+.F4HL:D#-W$ D!V-R+\(J=J[/8_Q90.C*!?NJ2W#?%4W7
M8+S76L50.-@'+B4I<&?0 EL+.<9Y*"<XY9YD8)DF;+!,Q*Y=@'2:V=@0^NA-
M&,;,B?)Q)1U"Y4T$EP"Q%'8A^!OY$&)$U:.0<U-0/FG!92E6#SYMKX749_:E
M24A7/A)P<8PB8*J-%?A-!S_%S%F](VE#(P4EB!8 D<Z$B]1%$Y5&35X9-4CF
M(B!4.NXV$&85JD4M+08Y*^UB"X)>$XXC%XE)Q@V -0^:U''$ NEFK2NI&K11
M@=5#<:A];F[:#G%<BKPB<FIE"N!.>)@81D<74CV / 5$A21@A0Y8QJ%#+0D!
MJ4*2*>+4^O<RN&.93$L""X\ _CHSUB3QO"'_ #L/R=!^=>JN/S \R/HT,H%D
MJ'_2OV@-6A'_ )V3\$9OZWS:ET[QXB);@OO"SZB 5:&/^=P??CMG_:T<;QXB
M 2!_(3S2L_2$-8A Y\:9/?D,( ]XC)!^'0L?Y@.13_?PBP:W5/N=*V'F+PPU
MJ 2>.JJ1CNQ&!"N_/L4GN_/R]W5@A6A)[P?GI%626.1(I9CKOK<<(3QS31C^
MS+GO=E4<^_A&?SC4%)%_4?3Z_2)(33LI'(&O-R?)H158I2\<564>'N)B+)]T
M E!*<G!)3PG(Y$:!QJ?+V@0" ,H#;G^I+/P:&FK4HC JRTCU"(LY)[R2I"B5
M'N*B>(CO.GSE @$,*#5M>=QOL!<Q;*I5(79XXC52,M?;X22)L4)0&R\"HLE2
M$_;'F@,D$X7CD>XP0"03=Z#B2-.?=5M1$!DI*18@N=6Y^5B3%T16*6D)!J82
M,$!2HZ7"O!P2H%K()Y$9)/"1CUF16Q%+U$  ![_!I32%%:I@43XW2!Z,1!\W
M5<OC/SZME.X<W%?.)AQK5+/?6$GWX:?YO4,>'B/>$)X[I8_YW'P0D_H;T(;=
MX@^D(/'E+_=C_P"2'\UJ(0>/:7^ZY/KQ# /YVM(0B;@IH*O[,%'/E]JC)'HR
M T,?T^CTH0[R@IO[N'\D_P#X](0>4%-_=P_DG_\ 'I"**HU^G*A2DHK+:G3'
M>ZOKXOV *#:L%X< RV3@*YCUY SJ0";0@@W!3A&8XJNA+G9V XIJ,"V5=4CD
MCS<*;[^!2>03@<SSU'/YRA%2NX:;@?V8*O<,0<O_ (9TA#/*&F_NK_\ *#^9
MTA!Y0TW]U?\ Y0?S.D(/*&F_NK_\H/YG2$'E#3?W5_\ E!_,Z0A1<=,2<FK*
M2,=Z8J<^]^Q#/O:0AAN2E*.#5W!ZR(WT-H/OZF]@\(/*&D?NR]^3+^C1CN/@
M80GE!2E$-IJ[JE+/"D&/Z20![,>GNY?]YB+CQ?\ 2$9$&7E#S9;IXE%?$4#F
M"$X\P)41W]_(>C4=[>'U!B&Y^G=1J0IC23_?COP-D?[&H[R>;?0")ABV)*$D
M]I<5G(_8@<$]V>)([U82#SX2>+! P9L]K&^AWQ8$/^$>?.CF_K:+-(9I[$SM
MLEV(S.7%+"9;C<=,OLC:T/%GKG,/&.A]2WG&T*+33F).&>L!.24)A01U:E'>
MEV' 58<.^UXU)IDIF9E+0BC,2'_$"Q!=[@D<C=GG+\9/%PSF&QPE2T(+*%-H
M2!E2LX4E#84#@I"4A82>(JXUR$S"Q*%AV"7!OH6KHY-*L-+A,DI"@E<L_P R
MLK9L@!!U/*Q;OBE54:>VI+*JG&"G2.%M2V$K5Q#*<A:BI"$^;CK5H4K ;*>6
M56,N>02$+S!V =GHUJCQ:Y%7$8^NPJ2 J:AE42Y#A[DG5C372E(8Y.II2\VY
M.BJ;#@:>;/95#SD\!:4 HI6E0)X1@GFI)!&,SU>)=+)624DD@*I5ZN&T-@26
MBJL3A % KE$!0%2"Y8\:G=OT$5U/C0V6&6J<ZS'B(24LMQ6V&VD\\D-L-H;2
MW@G)"&\8YJ'$2K6!86G\22]F+ZEF<OKOC<0N0I($H)8A^R6X$ "FZK/%RZAX
M^;VQSB/HZH$>O[T^CW/S:@*20P%=:U[QY1;M.[#)Q=W;?07X0_LTHC EKSCO
M+0'=[O GF??!TB"D*9WI%0RPZT1UCZW.:C@I\WN([P!C&<CN[L#TZ1:)8_W.
MQ_ M?R$ZE5SS/K$)L.0](:G[K=_Q=C_62-1$Q4:0@TA!I"$(![\_ 2/F(TA%
MO<?#9(!4".?""4)P21Q!2B2O!QQ=6AQ0Y)X>)204(:IYP<OL@44D@'B5DI.%
M)3U?'Q>K*>)844I#2U%24(1&Z\M(4I04.%).%*:41YCBTH!4ZD*)"?.<XD1T
M!+Q4\ VHAY\M8>7/3G$?6*/,I*AC.1YJ0"K"?/6$A(2>,*,@12I:2AE+BTK0
MEW_/EO-H=WSY?R>&+()R%)6.X$</,#N)"5KX0H>>D*(5P*3Q '.D(;I"(UGF
M.0/+W?=]1&D(:"._"?<',^KF>?=CNQ[OP54"H97(%^S0OS.G=S-H@'*L&A+&
MAJ+ZC=WU]= =)??&C='W:FY-PJJWVIVG1TLTBEA9"JM692@S @-K5Q!GKI"T
M)<4 DAL*<6XE*#KT/1;86)Z2[3D[/PP)SS %FA E@@J4;U(WL#06,>.Z;]*,
M/T4V-B=ISOQRT*ZI+L%S"#E2WY1=0%<KD Q\\3MZ[L]+1ZXKEOO?2LVLN#6*
M%36;(I5+N;R8A^4M59I% ;CFWJ@PU)S492XTMV8*C)2EHS'5")U2&OU#B-D]
M'>@DG9^%G;'1C%XE)!GF7*6H3DRS,4E2BD++A "0^3,6[(-/QRO;_2;I[B<;
M.E[9&&3*"%RY0F+0CJUS4R7$LA:4Y53$%0RA92>R9A!!B'1)N=^FWM4:7O2Q
M46[)K[]MS7WEUM$!ZKPHT*5*C2*A2Z_5X5/==3.:BT]IYPJ>J']CY1A34N-"
M$]*^C^&.' V#(3,Q<I$T2^IP[_Q% 9)<N:I*E3 &SI&8)=*@5)!*L2NB?23$
MC$&7MF8!@UJDJ(FE4M4R6IG,R7**4IFNTLK4C,0H*"2[8'N%T=MR=N)<-=2N
M>?5K<?K-8AS;JI$^K3X-+H-*ET"#Y1&GQ:G*K%7$B77# 32*1#DRF:G39D)Q
MW*HCLGJ[.Z0]%]H)FJ5L1$N=*P<O$K"Y&%2#,6E9^[!+_P .:D#K5"8 .J6%
M!3@QPMH[(Z4;-F24JVJN:B9B9N'E3)<U:I<R7*7*EG$!:9.0R0J<4B;F453)
M2I9EI4T7NY.C;7K<H]QUI_>6GKC4$RI*6"_=R)"Z31466J\)-8;B.SGJ!4[2
M<OFE1JI0);#]9[2Q-9[,AV.M Y2.E?1>;/ER_P!WA+*Y2EEY>& [/W@(4&++
MES$X8KEKEYTJ0N5VB"2.RKH7TK,M4\;:44HR=@3E%2@9>'F+00O#IR3)9Q*4
M3$+4A2%HFI(44I,S0U^T"MV%>EPV7)NBIU9^W9ZX#M1BU6KL,RRA(4'41W9C
MKC'$% J86XX6E<2 ZZ$A:OH.P\-L#;6S,)CY.RL/+1B)29B)<V1)*T!0"F.5
MPS&E06(</'@]L[3VQLG:.)V?/VAB>LPDZ;AU+3,="E2IBT%0)2DE)*3E)2*5
M(%8Q#MM3_;5BMD^[6JIR^*4GYM=@]'MBEC^S,"UJX>6:ZW'$1S1T@VL7_P#$
M,30M1?KQA1,J1S_9>LX'?FLU3O\ 1WS.7Q'/=R[]0.CVQ1__ $W!_P#3)2@>
M"6?OBJ^D6UDT&/Q1)LZZ?+EO" SJH"?[,5H#O&*S4^?NG[;/Q\L]^!W:G]W]
MC:;-PG%Y0/+7>8E/2+:Z@XVCB$-^)UFYLS$ LQ?5Z0O;:MC(K-<!&""*S50?
M@(E@8^#/J.G[ V*X_P##,)K7JDT@>D.TS^+:<]34K,TW,7AHF5,%2UU>N)!*
M"XZ*O4S@<0 X^"4EQ95Q<",A?"2.[)!M^P=B)!)V=@@.,I-_ CPO$?O)M- +
M;1GMN2M0<L6 [526II 9E464H16JN%$I0A"JS5@HK6@%(PZ^VDJ0LC#0<2MT
M(6$\TY%?V%L4VV=@F46K(0;.:.[$V(X@1B/23;6=+X[$A!<J=2@6=DG\1H;N
MH%@0::JU-JJBD&KUPA:D\.*E4U* 6$+0'1VD.,.%M9):ZMUP=4ZI*5H:<6F@
MZ/;)JH8#!@"KB2$A37L&N.#.!NB)NV]N2U9CM&<<O:*%8AE97(%*ON<D@M6M
M"T3JB22JM5E82&@KAK-4X0'#A+@0A]UT-J&5I"VDN%*26D.I*5&Z=A[(;_R&
M#!&JI2".]B&>UQ4 TJ#?]X]MJ R8V> S9>L*K"KMDJFC.FK DAX1,RJ E/C>
ML#' %*<JE304K5G#:T.S$K1UI'"T<E7L5J;'&$:O^PMD%A]PP5+-*#,:U +U
MT):!VYMETJ5CL0Z@IR%+"0$AP35G8U#FMM\1.5*>E7":U4T9)#?%7)B2I05P
MEO@7.;<X@H%)(03R*@D@IS7]A[)0<OW'"I<EVD2ZT<D9@UK-_;)^VMMJ9MHS
MPP!("U%@=[%ASX\(?V^H<B:M6$IPH*6:S52T%)!RD.(<4"1RYJ2E)R %>G4?
ML+9"OQ8#!K-&>2@-O!R@/KH[:7$4_;>W;?M&>5:'K" VI(*GY5!.[2'(G5)0
MPJJ5DH5YW":S47$*&3PJP)/ H@ XSDI[R$YU5?1W8JTE"]G85C0M+"6.\!W!
MT#O9M\2=L;<7+*?VEB004G,%E@14L2[\145X.=Q;5=(K>79BN0JQ9%\5]3$9
MQ"YEMUJKSZM;E5B-Y4Y"E4Z?)<9CH6@*2F1%7&>:XB4N <M>;VY]G_1W;."G
M848*7*G)0>KFH "TJ(=PM2%$6 .6E.TX-/1=&OM Z2]'\9)Q.'VEBERY:TB?
M*F**I4P.:%"2E*NR[!0)W,2X^EOHZ;W4/I";4V_N'1F50GYG6P*_1G'4O.T"
MXH)#54I <2,.,,N%N3#>'FRH,J-+; ;?2D?C/I3L&?T?VKB=FSB3U,PF6[.9
M9_"00!>W'*2!6O[[Z#=*\-TLV-A-I2U$*FH*9X)+(G)JI("K!F4*J("@E1S)
M4!N1;:O'$1WL3:FS2)Z5U#K"DQ5/3*4!!#(4.L;J1:XE+P5-*AIPM/6$'SB&
M)#L,S B@%%$$!WN0*[MSL?:!FU[*U .2Y 9K"X!/ VW15<R!G)P$I)))X5A"
M>)HY)YMCA!5RXL@^C18 R@:.#O!>Q%J>-:VB7?=RX.6/>_EXIJD(-(0:0@TA
M$2B0HX)'=W*4GT?X)&?AU8**79J[XEVW=X!]80J)[RH^^M?UM4F+-*#7?PXQ
M9("G?1K,-_"$S[_XZ_K:QYSN'G[Q;(-Y\O:#/O\ XZ_K:9SN'G[PR#>?+VBW
M51M3S$9*8*9_#4J>OJW'EMI8X'LB8"'$E2XW[(A )XSR*5=VKH)4:MH-=7KO
M)&@]8HM(2 Q.ITTTM2+DHG[Y7I)5Q8ZP\2@7"$G QC@QR]B3C6270GB6-VH^
MAL7#<O*$FIH+&AJQ >]'\!2&\_OE?C*^G64@'?XD>AB#7AR@Y_?*_&5].C#C
MXGWA#5E0')2N_P"^5[ONZHL!A>^\\>,(CXU_?*_&/TZQ,./B?>$'&O[Y7XQ^
MG1N)\3]?G<\(3))R2HG]\K]"AHA1!6P%Q=S9]7>$&??_ !U_6UDSG<//WA!G
MW_QU_6TSG<//WA%'4$*<A2DICB6I3#J415.+2)2U-J"8Q7Q@(2\?,4LD!(.2
M1J02K0$!GI8=_+2$.BIQ$AH4R8ZD1&4&,'%*[*4H2#&XPH\8;.4I62>()R#@
M\Z35, S7L0Q :@-7^A@0VKT^.+ P]W*$@I4H'(&>-7=@^[[FL:5DG=31QNXP
MB#K'/PB_QE?3K(YWGQ,(.L<_"+_&5].CG>?$P@ZQS\(O\97TZ.=Y\3"#K'/P
MB_QE?3HYWGQ,(.L6>]:S_E'Z=0230EQN-80TE1[U*]\*4#\8(.I%-!R(I"$\
M[[]SY1SZVIS?TI\(0]O/6-^<LX<0>:BKN4/OBK&?3C!U((+N!0$T#>/"L(W^
MPD=6VKT]6!\&!] U2$2J.!DD #OSZN?=[OQ^]I"*22>)+8XA@N CS@@**4J6
M$J*E))!QC".(Y(*APYTS$ D!W#,QWCP--;;GBK%QF+ %Z4- 15]*U'*NL<*[
M^]'_ ',W8W)I%T4JY:/!M.BT=- 11)#M<;J4BGW4FJTW<,JG4N?'I\%Z;195
M&327'(=6(JE#C\#].;<E.GUFQ-L[-P.%F2Y^&3.FJ!.9;=DI*2BS'*,M15W4
M'&9X^<=*.CFW]J[2D8C 8Y$C!RR$*DC.5E*PH35."4!6565+I(HEZ B-;JZ+
M.^-1IB7:G>MM.7C<-'N"W[TJ"9=S"ASJ'4)UM4Z%'@0D" X719ULJI]491,I
M[[51JDR0W*X'&W'=P[?V0LI*\$4(1-3,2)>0ETA947(405*4]RD,EOY@.4OH
M=TD2"J3M(&;-D*D3ES9LQ#(*I02E&1#%D2F)++7F6"6RDT](Z&]_17F:A5:M
M9CM?AVY9UO1;BABJM524NUKN?J K<HRV94A%0GVNBFTMUTU&>^J5',23+DQ&
MVG5V/2'9:9\Q4K!JZJ8F82B8$D!2D@7!"LH.8I9F!I2T#H5ME4B4F=C)?WB6
M924S94U>8!"W*F,O+GR@!V.8AS4N;(ST*]S90C1JG<%"IS41V!XSK%OUZXI=
M8O.;!J4^J1KGN 2X$4-5B X]%CM07'ZBV]'9=9>J*H_4QVYPO2/9V&,TG!IF
MB:32<@$2Y9#*2A22DN:L5.0X<$O&OC.@NWI_W="-I"4)"@9JI2UJ7B59E*"Y
M@4G*DH=- @)-:!Z]R='VQ+IV\V_IMM7C5X5;N&._47ZC/IQF*AOJF3GY#3C1
MFMH?;+C:T+<862&G2XAE:FDH&O)[7QV%QF*6O"2S+E%@E.@ !HXH;L*[W<DQ
M](Z.[.Q.S,"B3BYW7S05%2R""22#J!3F#&]T8"D@^R.>\*R!@^LD8Y:YR68<
M@]&^E><=ZKZ-R^"_")2 H$$9!_[_ $:M$P!(!SYWPJ41\1)&D(BC_<['\"U_
M(3J57/,^L0FPY#TA@SVIW&,]F8QD'&>MD=^#W?\ ?S[M1SM$PY:EA:4A6,]_
MFY'P<L^_W_!Z(!!=JMY\H!VJS\/CQ(@DIYDDY/,CA_-H"X>U_5H0_4P@TA%@
MJ@=[%43&ZSM1A2@QU PX7>J<+2 M);4A2G.%3:E. !20.XE)0CPFI],\(58E
M AVA2:5O#?\ /NRA;^U*P;LN&\60]9%V;A;ESZ);EM[BSY\N<]XCM"G5*%?&
MW%9DPJVY2[6-9H0C@4FB1R^<H?6\02[6Z7-.A[7V[<]#Z1%3O39N34MN[<IS
M-[7==-J;G4RG7U0:S9%\C>RR+RV^J$#<MG;V93*#=VX6]6VM\[>5UV%<\2J6
MZ'IM88JJ)L^M!I]&)-].>D=)='RT^F)2MX]BZING<M<JFV27.F\_5Z!(I==I
M]5MQ52WOIDS9X[DW!4MPJS"OQN19:IIL!QNV:2:)2REN+$ALI3$8 ^?/G\=J
M[HCGI\I'JBX"%'(/,GGDGB&<)QE*<!*0$CV15CC4M2E%10B/2$1+[Q[WZ3I"
M&I[QZ>8^?Z-1[=_C^D S@&Y+=WA^D>1/A>(=3>VBL&1'2ZY2HM\LFK(;#G4H
M#T*0U#5+X%)2$=K6V&^/O<*4IX3K[1]A\R3(Z1+3.#*F2U)EJ4$L25!JFI-+
M/?E'YO\ _P!1G7HV!@YJ5+ZE&*5UJ0Y!!0H + !8%Q4LV\$U\8]O[1W+JEK5
MVX;&JWBUB/583+M'CSDQZI<-3MZ)*NIM5*C]4I$B5;C%+<J:64K:+SG5I;0X
M"IO7Z6Z0;4V%@\=A<+M7!B>M:"N5,7AA.3*,Q<O"C*LETE8G*2;IRA14P)?\
MH;%V5MR?A\1C-E3PC#%:4XB7+Q)D3NK"3B 4I+9D),G-F*E+"PD(EJ,;'?H_
M2PE^+*VJXZ]QU:YJ-:T5QBX(45Q%P;@4VD1V&JC%AQ6X\-%3AUZDP*M6)4>2
M(<ZH,-OM*>+CC7FINT>@DI85.P&'6C"RC-$U6"2>KEX2:I!3+ 2!EESY2@A
M%4%2Y8$M)5'>P^R.FRS)6F?B\V*G=6G)C0KK)F,0%*6HC$ YIZ%(1/45)0H$
M2\0M,Q>2,>J5B=(5>Y5JV)5JA4IUYT61+O>Q9TRX&WJ*S4:\Z]=DVN6[6IK!
MA+J-:>A3*JN V'):Y3#Q$9@<;R-V1C^A$O XG:$K!88X.<H87%"5L_\ B94$
MX=:9TH)4M<I#*0HA/5A 4NB59AJ8O =,1C\)@)^*QB\6@_><-*.,R]6N;+1B
MQ,DSEXH(2N84A>=*Y<Q<XI[:L01+B&EU_I,;@6W)KU#N+<*\:'4[F$>H0Z,%
MU1Y^X;<AV_6VYU1MJ#$>CR4QFI5O*<E2&!'E3&XR)ZY[S"7UYITOH+A,9*DS
MY6RI$Q& E3,.K$(DR9<K#3IF("$RIBR@)2DF;*");*EH_P!ZX4,L2E=-\7(F
M+DXC:V)DS,1/3/E8>=/F"9BI0DJGF9+1-F3)J5!<@S)LQ.8KKF4M!::X=I-^
M+UK=N5JYXE0K-0O2VZ178UU5<2!!;AR.R0H].K-4\5Q6HU8@I>9;?@E#KC;"
M4K3(=4A:!N[-Z1=&,%AI^&V<)&$EX1<PS,-(3*2APZUKEIE+(6F95:5@@+S4
M27$:FTM@=(,9,PV,QDJ=B)^+EROX^)7,6N8"R4 S9BC66DI0L*6\LI(4  ";
M"KH\;S)JE?HJ+&JSU2M^4MB1'$>3%5-80S(?-2I*YD9B-4J8IJ,O@EM24%Q:
MV6T-*6Z$C83TRV--P\O%(QDCJ9BT(3,,WL@JFI1V@A*W5VC3,"""[ &-0]$M
MORYJL-^RY_6I[10I#,D)*UDJ.Y(<*&9)!!231\9B[3[FRI<&*[8%YTY,XL+$
MN?;58:B183\A$45.0\8B$JA-.J5UI0>)"4**L8&=J9TLV'+E35HVA(G*E9QU
M4J:E<Y:TA^J2"4Y5EJ)()KI&*5T:VV9TM,_9RY4N8 I,U4N8E EE>0S5+REI
M27&:8D* +@/:,9N2@3K3N&M6M5NI-3H50>ITU3!*V5NLD$.1RO"RRZA274<8
M"N%8"L$$#K[.QJ-HX/#XR43DGRPL)ME)'X5L5#,EV+%G!9Q?0QF$1@\1/PLT
MRA.DS%(4%!1=CV5(#(5E4*@D6+L#FBQC'<"#[V/S?TZWF!(MX#E4D?6.<4(<
ME2$ :DYG-?Y7-AKP(O:+37GZG#H]2ET>"JIU6/#E.TVFI(2NH36X[KD6&E:B
MVA!<?0VH.+=;2E24DGNUKXI,TR%B2 5L2 *.0*4<7M?RI&]LM&SUXV0G%+ER
M,/UTLS9DQ*E)"'.93!SV;EDDM;41QO'MSI.MTNC4.5*K+4^16W[?N&LIJAFL
ML6O>"Z+4W;DBKZ]AHU6SI\"M4E8#&&(M5B-PU/+#LI7CYDG;PR *<YU)402$
MB6L)49AH I4I04A 2D=C*9CG,_V0X[[.%==.2K!2SU$N;)DS<,L"9B<&9DN5
MA4I$PJ3+QDN8B=/4N83UB%I0)8 !ZTM&@RY&U5Q4NZIMR1KJFUJ\F*?-55)4
M:J,T=5UU-= D0*E'EKELRUTE4=49UY_[7I[CT1/[,LGT4B1C)F% G35A:NM!
M"%"CS%! !%0.K H#F3F':!S/\GVMC,*CIQ(G;.1@9NR),C9TZ9+5APJ2J=]T
MPPQ<I<J:%(4E,]4U*F 1,7*ZQE I?EY5I[V4REVN(=6OV4'+$C+O-N3<SDZN
MBOO77#-7CT23-F*$2L^33+[-,>.8U/9<2TPXV^\VE/"5@=L($M*9LT@R0N85
M3'45YQG2%$_S)!"2"D)?LE(8#Z;+VOT/Q&T]HE>&V5+2-H3I6S0C B7),E$D
MHPTV=+0D%<H32@S'3GFL2L*J56.JT7I&A*I-H/7.S1F&+I71J3<E61-N!=(G
MS(S-/IM=DN3U*%PQ@[(G4V2MYZ0TVT8K[I<'",2Y&VD*3U4U:PTQD3% J(<!
M ZP$D*2'*%',] I5B-X8WH)_$D[3E;,1/4K#=9.P<A<N2F8@+5,5*DG,DR)A
MR(GH&4MVI2 .S'I1M!<46@6E4*;<U0BM2ZPFTZ7)35(#55FPF"I:KGJK%2=B
M3GV)3,=MJ$KJWN+C<*F$N8XT[>T<#M2><(9,R:R<//7,RS%RVG(0@R4*"5I3
M,0LE04E86.RX*36/F2INRDSL<R9"I2\1FP^64%$X4S%9TI4M"NJ6E.0RE2^K
M4Q 5FJ(W=3V^C348J)50D4^BNL1__)[,B[5NQ9;+ZY$14)4B1-;DB26VA.1*
M[2PI+JFV&V$^PXTU7265U>'0554@*F$HS95 !1!) #%\E-.UF+QG"=@?Q%DT
M""I* E1!6$@I2IP:$476KN,M,O-%?ELU"XJW4(K++$"959[T)J.R(S"()E.(
MAI992AIMMKLZ6R$AL+\Y1<45$:]QL^7BD8>4,5,5,F9$YE+8J?*'J +G\3B]
MF:/*XK)FFG"$)D9SE8K<)=P ZE>!+LSAZQ9U %90$\1X3@D$I!(P>+'(XS[$
MY!)&4G!&MX$.2#47.NZ_=Y'6*(_B2@$.!G3UA2&*B<S5(8LQI=GI:/=_P3,>
MJ)VEW*E/=8FD2=Q&_%85GJR\S0:<W42UC#:AQJC\:FDI2VH".D)3&#:/R1]M
M\_!KVYA$R @3Y<K$?><H"2HO(R%3$O\ AF)K>H!%3'[0_P#T\RL6-B8U4T3.
MH3.DB1G)*24(Q1F-<!PN65L!F!!>Q/J*\EH5B"M3<OM":14^K=2.*"EL2J5U
MC#R  3+=/5N15\>$LQYGF**@I/PQ!:O)G<_FLVM"W&NX1^E: D7!RJ=R*F[:
M:,+U)$5I!SS]02#D'B2C*$D@<PHA/%D\RE2?5J)@ /*AU_"P?OOR:)MPNXW$
MUX[]]"XT@UCA!I"#2$&D(A7[(_!\PTA#=8YFG?\ 2,DO7N^L&L<9(-(1;*LA
MI;$0.MS'.&J4U2!"R%H<3(RAY\X4.RM*PI]/""M. %I 5FZ->8;G4CTC',L.
M_P *.&&_G3<8NA.>9'-1*CSY#)("4C)PD #EDDGO.LZ"ZM+Z<E4J7#.'!B@Y
MO0__ !K\IRA-9HB#2$,7W#W_ -!U1=AS^AA$6L4(-(0:HFZ^?U,(-7A!I"**
MI &!,"DO+08KX6B.</K26U<2&E $I<4!A"@"0K![L@R"18M^GUW?K"'P@@0X
MH;2XA BQ@E+QRZ &DXZTGV3B1A)4 G)"B1D\L4Q14S@4N02:UIN&]F%XDOJ]
M;.---3$C_L!^^'S'4(N>7U$1%+K+"#2$&D(-(0:0@TA!I"'M_LC?[]/\H:LG
M^;_E/TA'0#'["U^\3\VJPAZDA0P>[^N/S^OEI$'3GX4/]N^.;^DZ[N1"V[;F
M[6UFNT:Z&;EM.,ER@42D7!*>I=2KT&DUE#E-J]$KK*F(U.GR:DJ2W&:[&] 9
ME2Y"::U.:>ZNR$8:9BA+Q2DHE+2I)42!E+I(4ZG ( (X DW:/-])9F/E8)4[
M9W6'$2UH(0A(7G0QS)*6)(+O35(>CQQ[4>EGOK:\:#2I.T;LZM3*U(I%':G4
MRZ6JO6)--HM?FS:.B#3Z!&34*TMRF4]$FZ:%":L)E5RLO1Y79(4E>O8GHSL%
M<J9B%[3$Q"  )<F=)2K,IFF$J2II0_B I++=) [20%_.QTRZ52%R<.-BY5S<
M098FS<-BB\L2YBB@I1,053CD1VT@2QG2Z4!69&:7MNITD*#>TFI0MOZZ_1FK
M9I,J+;=(;\>4Z=*0-Q9CSDNJB@I>C3IXIMN19%,:EE<%<F"69KR9BV)FGLS9
MW1^9(GR\1BY<I2"LRYJ'0M8!2 DI((7F!4S)H0/YG,=':6V.ELC$2YTC9DUC
M+052&Z]!)*R3F0Q34#7,:#,04I%=1>D/TAE7M95J5K8]Q,&LUNI0KGN:G-7%
MXKI\2*[($&5!?=IZG ZJ,F.XZ_44L1'U/*CQ) ,90%)NPMC' S\7*VLCK)9S
M2\),,L32"[E1"69P.RFH>YJ\X3I5THF;0P^#Q.PE=4J89<[$RY.($LAPE*Y2
ME*&4)!.8JSA0!HEJ:_KV\W20L^[=PI]+MJ[KTI]*J-U--6M-L*3&I4"G1)D1
MNT7K:JM/H-.J%QN51M<DU%I%0KO5):3(0Y"0%!6? [*V+C98EXC&R<.0);+,
MV6DD5,Q)3,9(:C**MX(K73VCT@Z4[.Q^)5@\!B\2#UF66K"K5+E]H!"DS)90
MI;A^P!8CMWB:'TG>E+!$.94MD9M3\;W!;C$6B0;6NQ,FB4.I0TKJ4F?7%%R(
M_,:?*TA*6D)B)2EJ8V2 3LXK8'1B5UB9.T5$R\--6%C$84I7.2!E04!"U,1<
MIRU+4-37 =*^F\U4HXG8R$2YN)E(4E>%Q8*)"F"EA?7ARY<!6<[TD-'IU"D.
M/=7U@ 46PHI'G%.4\^(Y!0<D#A4D$]_+NU\W4!UA8@L2.R::M9]^\#=2/L,D
MJ,M*E @J2DAZ;GH=-PN-1%RU,9(-(1#'^YV/X%K^0G4JN>9]8A-AR'I%,ZYP
M271D JC1P.\DJ+DK  !!)..[D,9.>1U154L'<D#@U^>D!^-M,K\:/;3W:.8-
MS^E99.V%UN63,IMQ5BXXPILR=3:/#BOOP[>EH;7/NA:7YC*GJ-1>M::FNMH+
MSLIY,*$U)D(<2CKX39$^?(,]&3($E3J4Q8&U&<N_<'Y\3&;:P\C$G#J+*S)!
M2Q  (!WL38UHY9XZ?IDUJHPHTU@E3,EAI]HJ3PJX'D!Q/$D\TGA4,I4 H'D1
MKF+3E4I-'!((#T(+-77?'6DK"T@BQ&8;](K]5C-!I"+>H#B)YY!/<2,X)QQ
M$!8&3@*R!ZM(0B4I!!5Q*4#Q$A7!Q*Q@J4E("5*Q@ D92  DC&D(C6$@X2,
MA600E6<J44C)3R2C/FI&$XR% A2@4(8 $JXD@I/G'S5*P2HDE2@20L^<O!5D
MCC)', A"('.2N1 &$@ \\!*0A(SD%6$I RK*O6>[2$,S_A)_K_E:0ABN9[P>
M7K ]?K.D(:4\@23D'N!&",9]W^I[N>H42$DAN9%OF[6(*1V5DD%*@P_E[_T(
M\XU#O;M);&]^WEQ;=77$+M/KT-R.A]*4=?"EMX<ASXBBD\,J)(2V^UQ'!X2
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M2DN"$2E,X*7N&CD:W>G=9%P>3D^JV+4:1%\B:U==SRW9$"4[9-P4J33XKMG
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M!2"#_-44H] QW4H'-XNVD9(-(1#'^YV/X%K^0G4JN>9]8A-AR'I%')'VPX0
MH]G8 258!!<D\> >144@I3W'F<$:@!UIK_>@^NZG?$+HE19RS?/&/*;="G;I
M.;\7K0X=Z[@7%39S]LR95,LW;ZQ7EVK;50?ZUFB>4=R52!,:;D-Q^N<=ID=U
MP#C>=+LM2B?;X54I.R9:S+"5?Q6(664KM)*EI%"U6J*<Q'S?:$B:=L*25J6Z
MI.<94N$'+,RI42"CN#J8!5J^J=)08M)@MA+RU-PXR%!XH#V4,I!+I22CK"1Y
MX22@*X@DE(&O%3%%4U= &)MSIQYDOSCZ+)0$RT-^1(N^@+O\^L5?:)'HAK(]
M?6H^KJL983M$KVFKY1.D(AXI!YF(YD^IQ'T'2$*%/>F$X?\ .H'^SI"#B=/?
M!6?\ZCZND(,N>T5_*H^KI"&D.$Y[ KY5/Z -(0G"Y[05\HG2$(6U*.3!6/><
M3^G2$1N,J(P(;B<^MQOO]?,>C4&H(T/BX^=W-FA0<$=XYU^>-=\:HZE  Q%$
M$<*P74D+&00<>A0(R#GEW#EJ%%*2 DEPU6\JD%OFD2DFA4 2+7H-+$<VM$2H
MA6I7''6H$8*7'DX2D8[E85@<@>1!Y8)YZN%E)!S*#4H6S<*#^_*,1ED@@D$%
M15E-0#:CCQ% #I#3#;4HJ$0\CCDZVD @!/F@) QZ>7(J)/>3JAFJSYDJ4Q#$
M/SWA_I%DH2P"DH!23E+5:FX,SO>L/$-)YB&H$<LI>0>7J[L>OT>G5A-614DU
MI0GZ&L09227H=;%K-P.ZEOHU4%L\C$6GUX>;Y\^_F#W\@?1R]>H,XI4"2HT'
M\I9J[F/SC$&2A2<I N[ZB@XZMJ_UA!3V<<X?H &7DY&.?+'K_P"[&G7DO53'
MNKR-]+OKK6)$A!;L@MO!/T-N8A50(ZLYA#GW9>!QZL:D3B 1F(?>_D'/G$G#
MH+.D4#421_\ 7].$0JIS(6DB*L>GS7QGEGEG!) SG'=GOTZU3$)60^K$L[5<
MBEH@R)22"985Y>(+:LQ;3>*/\7-+!S#6KUDNH',]Y Y8SJ0I>4 J)(%WJ237
M1O+N$"B43_N0P+@'1]&S"CN>?*&&F,)P#"4 HD9ZU)((!([AR'+F>9]'JS)6
MH@![<]8@293$&4*[WXV8F*"+34&H50+886PV(@CM,NH[0WEMU3IE'AR>,\'4
M9Y@!S&HSJ8 J4=U26MNH-UHC[O)TEI#L#H][U?Z#A%Q--8&"F"H@C'[.!S^'
M'?ZN?H]W1U$W5W$^@._YI$*E2T@94IJSCAWCP:CP&E,$Y[$0>0)#P.1W^D>G
M/Z<=VIS*W^D9.HD@DY$'B<UCR-+]Q&D(JDQ^\PE'_/)'Z /Z= HZGG4OX!0'
MI&-6'EBH#[DC]4OQN3"&CQE<^PJ! Y8=3G'N<CW^_J0M0H%'YS_2)3*DL72A
MSO)S4THP&OG6$-(CDC,%9]POH[OA!/I]S4%1*2Y+O1B0P[FBG4RW_"DAPY<6
MW:<8%4:,>?87/EDY^$X].?1RU1&=+C,IB7O3WHW]XN9$HLP3QUUIK2W&&JHL
M922#!4H>E*G4')]!QC&1Z#Z/<SSL5S*)<E)%2[$5T9AQJ[^)B>JDA/:2DD?A
M!<5>]_KOA@HT9) ,1[(/(B3R0#C*?=2<#*""DX&1C55A*DA':;5Q?<3RYU%*
MEF2Y:4!3I"06*0"59&>Q-0&NQ+TAB:3$<XD]ED+X"!GM0&/98 "N24]_"A("
M1YQ &3H 4I"7[(_"- #N;X+:19)27RYJ7S/<UHY-/TX 4;E&:55XJ1&3V==/
MJ <0J4DRP\)%,##S/KC(1U[<E.,*==BYR -6"F+W)WUM2NNNG(WB]K-\^?6*
MT4*'P@""]CO $@HP%@.8YJ"B 5D942>(*'+&-"2IG-N7M"%\11/:$C\K_P"/
M56.\^7M"#Q%$]H2/RO\ X]&.\^7M"#Q%$]H2/RO_ (]&.\^7M"%%!B'/VA)]
M'=+/UC^C1CO/E[0A?)^)[1E>]VOEZ?<]W5@HBQA!Y/Q/:,K\K_HT))O"#R?B
M>T97Y7_1J(0>3\3VC*_*_P"C2$6JKT-I#,<L1TLK,Z)Q&;*2IM3?7)XT-@C]
MF4G*6R.Y1&H.A=OU(IWP^7;YSBY>3\'F.QO*!&<)DXP<D**CC!*B,@=P!Y<M
M6!(M\[K'OA!Y/0?:#_Y4/HU.=6_R'M$N=Y^OC!Y/0/:#_P"5)^C3.K?Y#V@Y
MWGQ,!MV ?[PD?E8'S#4%1-S!R;DGOA/)V![0D?EFHB(/)V!Z(,CX9>?HTA""
MVX//,.1[F)6/T*S^;0 )=@*WH_J[=T2[;N\ ^L+Y-P/:<C\K_P"#4N>'@/:#
MGAX#V@\FX'M.1^5_\&CGAX#V@YX> ]HHY]MPA#E%N(I+@COEI4B25-(=ZM75
MK<PD#JTJYK![TY T)/+D /IPB"7W> 'H(6%;<0Q8_61E*<[.QUA8DGJ5++22
MI31"<%LG)2/0" .6JL#</SK_ &[H?/FZ*DVU ],*2KWI8&/?R!J0P+@#PA##
M;-./?3Y7Y8G4DOH!R#0A/)>F_N?*_+1].HA!Y+TW]SY7Y:/ITA!Y+TW]SY7Y
M:/ITA"BUZ;G[@E)]TS?S<LG2$!M:FY!,.3Z?[\)//T>Q[ACT@Z0A/):F>TI7
MY6?YO2$'DO3001!D*(((*I0/"0001Q)2,YY>D^K&D-_'RY1DHD26TA(C<(!"
M0.LXB.1/=@\O2<D'D?3R)P+T[G^4>)#.'>M*:<WTA.V225!321P\2DX4 "D)
M(3E1(X2M1PDX((!.01C4*4 0P41:VM_1]>\V&-)*BH+(0QH0Y+/2SUJ-VH%8
MP*^+'H>X"*"+B@.OBW:NS<%-+4A3)1-$"HTQ]ITH4 _'DTJIU.GS6',-2(LQ
MUE7LP#M83%S<,2J7V5K!2_\ ,'8@I-"% AQRJ\<_:6S</M"6E.)"9DM"PL)(
M+*9*DD*#%TJ2M22FH(4QU)QAS8W:EV-/B/V#;;L:IJXZBV8,<B8E5.I%+"W6
MU-I"EKIEOT2" LJ(C4F&@KPPWK<_;>U$S4K3BYX4[!6<A8N4U>P)4:@W-2]>
M>>C&PNJR?<L(4%)<=2E@" " &N4H0"PJ$I!M$J-D=JVZ3'H7ZWENFDQI\&IQ
MH"(,;LC-0I\!BFP9K38"0W(B068\%I:<A+#26SD9SC.W=JSIJIR\9/,Y+RS,
M*SF*"<V4G<#4-8NQTC,CHUL27($A.!PXE%6;JA+ 2[,5 ,0.R&(W&]3%5+V=
MVPD4>H4"785!=HE6CTZ/4J8N(RY$F,TIN.S2VI2"WPN)@M1H[49*DD-I:;P1
MPC6']HXOK"OK9JIA4225%1+ER6<LY >U[5C.=A[.3*$I6%DC#Y4I"<H9DAD
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M.L7]\=(1&MQ61DJ/+[XCYO>TA$:EJ(R 3[ZS\/Z!Z._OU(;4MNH_S]8FH25
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M!8>L)V^;[:?^57].H9[Q,)VZ9[:D?+.?6U##</ 0B1J;,+B/MN1@+22.M7S
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MN!3+EY<?*,Q2A7.@C(=%5)"@& ##FSOS)'VG[<1BYR9FPYYD!(2)>2:F8)K
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M*TDABAG(M0EP1OW1V]@=,]OXZ=)$_ 3$R)D["RUS%2IB&,TS@K*DU(&5)"W
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MU316*A6(SUMT!R@T:;:OC"G%E\4Z2FM2*S+G5>FRD/QG:K(>4607'>+$F6D
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M49!@U&JQY,:.B0@IJ)I(_E?4DD%V%0]@2]F(!+Q8(6E4QI4UIF8<$A16P_J
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MUJ#;TR,Y(Q&#C/5N)6Z4N$C5@M)MU;5-5BIH':M+/4TXQ!!"3G0LDA"4@(H
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MP<3:$\^):U*"0"1WX.M[%[3P>"PZ@A:2<H/XF#BS"K5)W[^,<G!;%Q>U,9_
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M.I8*,,J5_ ZEDS,V4&JB'152K',Y:Q$9U?9G-1*4G[]+FYL8G&3,V'RF9-2
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M6K6F[]*^%^$%(*DD@LQ8C0V;XT,[4&DDJCM8 XBK@"D@9'FK4D**5'O2#YI
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M$'E*[[0A_B?T:0AANAT$CQ?#Y''L?^'6+.=P\_>,@0X!>X>WZPGE2[^Y\/\
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MB(W;<B9MQ"%0J;MB7A9JXDY*K^A5&X;DI57<<8J#HAT^E4JD(?!\UC#J_P!
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M=#HYJM:>ITU%/8@2FY<5EUF)(AI*XKGT##29<C*%!)!!<%*5)S*4,I(2D42
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M6%%2'L<"T*!QK)+OWBNX5JVHX1CF6 O>F^+B0, ^ZH CV*QQ'"DCN2![#A&
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MEER>A#;RD2_G5R[ZTKXD7WQZ<J.>X) )4KS5<0\]17SQW'SLE6 7<]:H!2U
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MHR8+HSAL%/3,E39QRJ)RYDMJ<K!%M#5S=WCIIMC@#8"E$) R>1XBDY!4<=^
M!D8'/EW#7$4IUV8&NM+^U-UH]4@,D#=PKW_!#X_W.Q_ M?R$ZLJYYGUB4V'(
M>D-3]UN_XNQ_K)&JM5W-F;2)B5: L $XP<YY9][WOH&IB &#7OZO !U:, CE
MW<1P.9[O<^G2)A4J!'-2<^X00/<SG2$!)]!3CW3_ $Z0BE4T.+)RHGOPH%!&
M<XX2?7W^OEG.!I"(BPG*BE'LBHJXN%65*/>1W$!(2C&.:4I"LA*<(0*84H'
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MO]#ZVL==P\3[0@\15?VB]_H?6TKN'B?:$!H57]$![X2@?[1U #$G?Q??P$2
M^H',M">(JQ[0=^-/TZM$Y?ZD^,'B*L>T'?C3].D00VH/(O%'4*-5FX,Q2F'H
MH3$D*+X"%]2E+2B7N#B'$6O9@#))'=H_]OE-?:(A\.BU9<2(I$5]]*XD90?(
M" \"RC#G"5G!<!XR.6.(CT:H4ON %J#Z6'#GPA$KM!K"D@=A=','O2?0?4=
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M\^7B"X%GM;C\)OI'9CI3E/#CD,$@$94"<YSSR#G/HSW9[](F(\>:3[P!^?\
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M7\A.I5<\SZQ";#D/2&I^ZW?\78_UDC41,5&D(-(12NN)05!7J [LG) [O2
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M<::5(BO5:HN]:MM2I/;'VYO:65(;;PCIGT6"!+ZB:E IDZ@,1:P2PH "&(8
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M^7ZBI"F*PG,E*)L%82E24?:R@ZVZE*D*4E(*\DCD[2P"MGJ0E<R6LJ +RR"
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M_O+O</\ Z(U(^Z:YN[+$-M?\^'_UU\Z_!I!GPI/IC="3^,F]Q_\ HD:?X/\
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MD0O%2X/7EM^)(<=3)0VRIHA:E)PS?NY!,O-G!#$@6UJ*TW<^[=D#& CKE(*
M#^ $$GA4O5W\K1U/'^YV/X%K^0G6!5SS/K&^FPY#TAF2)3N ">SL<LXY=;(Y
M]Q[OZ\^1B)B0NA)P1S]//./S?-\.H<NS4W_/H_JT"H=M]'#T>XTM$:F$NJZQ
M14"<$)XB4@@#A4""E2?=#:D9Y\6<G,L-T4!)4020+E/A3=75KB')8 [R#[@!
M ^ <1(^%1)]).=(N4AW#@O>Y\_HWA"]4?0H8]T+)_,XD8^#X=0PW#PB8AR.?
MFI*@3G*BD8'NE9)/N:,-P\!"&8"CYO5@<.>:E^R[BG]E1Z2D XY\7N:C*G=Z
MPB/*CGS6T@8R5%[!))'"D)<4I2P4JRD#DD!1.%##(G=YGWA#5!2B2G.!R)2'
M$M@^R&5+<!*BDA7($ $<\\6)RI&@]?6$4RB%'SO.(Y9XW![N.2QGU^GO[]04
MI.@]/2)<BQ([X;A/WO\ IN_SFF1.[S/O!SO/B8C60"  1R^_<_2LZ90+..\^
M\0Y-R\- )SC/XR^_X5C4L'9R^@<^\62 HL7'$:1BM[WC;>W]K5V\[RK4&WK5
MM>DS*W7JW4I*8]/IE.@LJ?DRICZUDMM-M)4O(2HJX0EL+<*6U9,/(.(G"6A)
M420'#D[K&[5UXB-?&8F5A)"YQF!(0"3F(%!6X+UTH1S>/G$WP\-+TKKRG,3>
M@[T/IUV[5U&H5*EVUO#N12:_6F;Y71.U>-YUN6G;M8M]^ETV$S$D3NOJU7>E
M)IS?:JC I8*FD>KP_1S"E258A691;,DLD97I=3W<9@SEP*1\VVITWQ:2J7A4
MLAB00%K5V1VCF$OJW (=+*8$$T+#DF;X8;PPD"DQ:[+Z,FW+5(F4FX+AC5!K
M9;<J1$DT*U6),NX*HF2QN:ZR8M+AQ'Y#TA"S'=9CR'H[KK+76J[(V%L5( F.
M%%K+)!=@EF6 22X =RX:X$<1/2S;A6R9BU.DJ2#*ECL]I16#U'X0 2M3]G*2
MH4+6VD>'!\)94I-X1/UGMFW']NJ>BK[@L,;6W\X[9=,<=AL-2[B0UN<^:6AU
MVH0FVQ*4TOCE-H6E!"P,LWH[L.4E"@I2BM64"J="JX77>0 * FU8UATTV\HK
M8NSD$(00V8(S'_#@A(6H)*E$ J( +F-R5+PM?A/[7CU:9>NPNW=K1+?I]OU6
MOR:KM%N-3XM)I]TR'(5O3)STO<()BLUB=&EPX:I!:7VB,[&DLQI:%L"TOHYL
M68LH'^;.=+L,U0FCW(>L8IG3?;J#6HRI45&4BA5G9)_@G*X2Z22RA5.85C)[
M%\+QT\+YJ]*M^@;<[1UJM5Z&]4Z)2J=M]>O:JY3(_&'IU);?W ;,]GC:6VVI
MCB2\ZE;+*EOM/-MYYG138R$&8M1*4WK0!G!<K8"A<<*M&!'V@[<4I$M .=9
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M_&/TI.IS(/\ )_J ]$Q&5(L"/^H_1H"4G]J?C3^A U&9 _D/^9_5,&&KD?\
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M'O' G7"S.O6T-R[XN&([<5L46)(CLF1#IDVG,P*?&BUN.N;,4J,GT&"*3A%
MH=@O,26;5@&T<5!I6/#;80O]I)4E0&=4D(2!F"V"7"F4!4@CM)4-* !_<^VT
MO)H-)3(C-0I":?$3(AL</4Q'PPWUL5D)) :87Q--@=R$C7!F?C4V\_/EX]I(
M21+03?( W<#INLW"+WJD9X-(1;'$%140<9RD@C*5))YI(]1Y'/>" 01SRA&F
MZKT==C*[5:97JSM;9-4K=&JM9K=+JL^@094^%5+C7#<N&7'DN-%UM5:<@0G*
MD@*")BXD<OI7U2 $(;/Z/FS4RXC=#^WUMN5MVIHK4R<BG,QEU&IM^*%-RZBU
M&#3,]QEZ@TB4PF6VZVQ,IT*4TA#T5E:#>=(1EEM[<V+:,BG2[:M6BT:32;7I
MEDTQ^GPFHKD&TJ-(F2:5;L<LA ;I-.=G250XJ<(:+KBL%2RK2$9@I("CPI(3
MZ .82.[&<>YZ>?/2$-P?4?B.D(B6.8SRY>G/T:0AA'+DH=X]?P\L>K0>_I6(
M58Z6KNK'FAX5_H?5/IF=%"X[$M-+"]P[1FQ[[L%+YX&I%9I"5%^E*>! 856(
M2GZ>'7DE"5/ A)'+78V#CQ@L4ZZ9R4W ;<>3U/J8\QTKV6K:6 RRTYERWF ?
MF8$* M4BU:U J*?')$Z3=:Z/VS3/1WJMCU^@;E1:+7-O]QZ1<],1295MP4[E
MV]>R*A0Q.B+<-5KL*G2*1XW0TA=-+,2J4N:ZD1RGZ N6,694U,T+/!3-4]D/
M_P PK2AUN?C97,V<O$RUR&"@D#,DD]FCD,"X4@$BI(8*(+MMN]/"HR+NM7>&
MUAM&BF-[S6F[9M?E(NZ7-?I,*!96XEET6;0GY4=V53Z@ZF[Z75+HD)D<=?G4
M^L/N! K:RWED[+/6E:U&KD#/5B0IW).HI06TC!,VI,^[F4A"*J0O-U20Y2@I
M*2  .TDEZ,22X))$<V6ATH:]";Z*;#5IVG2O_!AK$&JQ*I;-)IUO7'>;#5Z,
M71+B5NOT^(S4%HJ41+]+J"5/.-SW9+U6FHD5%Q3ZNFC!)2DA2U+=V[9(9F8)
M)(#L20&<U((K'$G8Q9F=:4 ,N@$H!64 D.INTI*B,BE$E &5)"28]!ML?"25
M:V44UJ9MA2*Y)B^/Y2ZS4YT=ZYI52K&\M^;KP>T5]<!=2DT:ELWDQ16:)*DO
M07%TMR6MG,Y]"M=&RV1/2)JOXLQ2@7(R@I2&H:U22[W8/&Y,VRE?4$2$(3(4
MDE.4*"P"5U!!34J4&8):X<$QN3:SIT46G[G[G[M5S;:GQKDN^U*;&A)I#X34
MZO7.T4!$^AU*L2&G&H-F&)3YXI=/;A//Q(CRH+,AIY#4ENW[)692$#$) 112
ME#/9P"D9@ 02*%VJ[Q$K;>'3/FSER"4S,P"  E*7*2Q8!TLX4  ;69CK3<.]
MJ)?=V4BIT%#[<&E6?:UO%R2R(S\J52*6S&E.J:4X\2T'PMMAQ;CCBVD(4M6>
M[L83#2\,D!:PH@D@OEN :@DU?2C-2E^%M?&(QQEA$O)D0SA#ALSL,H J*:DE
MWUB_6Z2GJ\G/, !) /<.>">8^G(/H&^F8'HH58]I0-':@)%-]&-]\<.8A.8!
M*:FA(2U:T]R6K:-]6ZL)Z@*/"2L <9QG(Y<(!).>[ !))Q@ZVU3Y:$DF<A+@
M%P033O=FM_=B94V80F6A2U$L!E(8DLS\[5#.]*QZU="/:&MFM)W,KT!^!2Z?
M$4Q;Z)K2V7YTJ8V6%R@RXE*DQF&%+PM:<K4M!3[$Z^9],=N)FR#@Y*@K,5%2
M@ITAC3LL]03_ #, 7XQ]G^SOHYBI,[[_ (N64"6$"6%)()*@ISF<?A8%P [A
MKD1Z71'@Y4*TCMID!DT\&%P</B]74O*P%=RQ)\UP$<P$ *[LGY@CM$$W(.]Q
MJ_?^NXG[B5Y4E(JD,^K#<.!8U:.9NDU8N[FX(V^H^V%4EVW%9J]3?N*ZZ95$
M4VK6VBL-0[2<J])6M)5XTHEK7+>%QTI]I2'FJQ1*>RA:1(XAT,.9"<YFAR G
M*[Z9B:UK4-P:[TY..E8N>)2<.I0!*BHI(2$DME>C%@%:!FY1Q1)Z/?2I9N*J
MW-!1=57KU)ILUJPYMR;HS*I311/'EP7?3;6N2/)==57;@AS;<VSHT"XZHU-G
MMP&Y:53(_4+4YT4S\ D#,A^0%[.*<WM2CT$< X':_:[2M YF5I9R2>#, QT%
M&P$[*=/9^TXU;EUR\T;A42+6H%&?=W1J4F:W:%QWT9-:M]QQRL"0+EF4JCVW
M):K;E8=ETF"JITBF5!CJ(R#*I^ (82Z<P'(&H8T U](Q(PNUTS'7,6"YH5.P
M<$G\5 Y4 &9]7CKV[]J.DG7K)V#MER\ZBNOVY0&&=RK_ */75TFX':E+DT7Q
MJ]29ZFTU%JHO4VF3:<FH,/-2L5>0\A:7&^,Z05A^VR-3E#N-.XCCQ8[X[0D8
MU291$Y3I':J7))WO4LPJX<&\996]H=S;CZ.UD;<W!5JY7KN8N6W7KGFR[MFJ
MJ(HT&NN5"5XXK:'TS+C$.'&BQW6ZBZZ:@ITKDDJ1Q:PYI:)@*4@ AZD4XC2]
M>.KO&PO"XJ9ASVSF0MB2IB0]0:N6%M*VC7.WO1YWKIVZ&WMW7=?56J5I1[^W
M'W'N2Q%JM==$MJJU!A;%FQZ7/ATIFX*HHEB.XI%0JDB)&"R@-#@R<\R<E2<O
M5I!9GRAV>MN=2.%(TI."Q:)B)BIBBE)4Z<_9)<E) =LQ=JTH]8TO=&S-_P!>
M?W/JBNBZAN;>%Y1:0Y1%73;4BF2:$BK.5 [C5)F4X?*NZF7(T>13H%RER)1^
MT-M08_5-NI=JL(ZH$,HI%\C._%M!KJUXA1Q2YRD$$!2@RC-#(9P72X)+-0TO
M2S>H-KP:;9%D6U1GYJH5/MBVJ32A)N"JQU/QV:938S*Q4*E*>;;=?9X."2^H
MI8+@^QJ""A"><I*R7#L 1PK\;E'?ED2I(0H.6':S#1N=ZD[R78!HY_Z0^V4K
MI2V=MA:MI79;<S:&H;IVE=NZ=0I\X5)5XV/M[74W%Y)V])@.+B2$W!=M IU%
MK2B\ W2T5-*5+^R)&1!0D*=!<C4Z5KJ_=H7''!.P\V:4%*V8D'*[L6#4;6N]
MV %R>G)#RO'<4*ED%=*J[Y@IR$RTIJ-,*9RG%8 >BK<0E3*0>(REJ3PMMI2<
M2U(_$$V<FO$^%@0&T&I,;<I*P DE7$*J"[6T#5'?2D5*BI( 4%#UE7".-:?,
M6YCB[U*01[R01WZA2G9[U=];.?&GZQGH:@#N%A<#PAG$/ZE/UM5A!Q#^I3];
M2$'$/ZE/UM(0X95W G'NI^MI"(5@YSCO]U/>.1_;<](0WGZO])'UM(0<_5_I
M(^MJBDE3,U'OW1=*@EW>K?6#GZO])'UM5R'>//VBV<;CY>\6VJ.%MF,>U=CS
M48">+ 7UW$^$]F*4JR$O$A*U]R$Y)!U9*2-14CR>A-&Y^-(HI0+7#/I7N%7B
MYJR 2<8XCA(4E7 ,DA(.1D'/$2<9)/IUD06[JGA>FX,^O /$"_<Q(H]&?2NK
M;^<-XL]P)^%/TZRYN!/)CZ$Q%/@_6$*B/1\9 _2=55,R_P JCW09_P"X'K#5
M$J&, <\^R&J*F9@V10J]HECP\1[PS!]SXQ].J9OZ5>$&/#Q'O!PGW/C'TZ9N
M!'=?E!CP\1[PTG!P?G3].IEI?,=YT8M>]1]8 7>C<OJ1"<0_J4_6UDR'CX#_
M +HG*-__ ,?^Z%XAZP/?(_03JJ@4M0E^7O$$-J_A]"8HZ@X40I2DO]GX6'5=
M>$\98(;40\$@@DM\U!((SW:@$U#,^A:OK:(A\-23$C'K>NS'9P\3CK<MI)<*
M?VJED\9&3CBQK&4Z.3K;?Q)^NF^)W<M[\_.SB)71Q) 203Q ]X'+!]9T RER
M[,U0+TW$[C$13]6KU#\9/TZN"#;T,(.K5ZA^,GZ=3"#JU>H?C)^G2$'5J]0_
M&3].D(.K5ZA^,GZ=02WQ_2$,].,C/OZF$&D(>W^RM#UN)'YQZ/3J06?B"/&$
M= ,9ZIL$$>8GO][40B72$4THA*$DG'V1*0H)"E)*\HRD$%/$>+ARK  )R1WZ
M;N?O;C^L06:H?<*7XOI>/++I8=(S=[:F]M]W;*K*HJ]N=EM@KBM"UG+8J%TM
M7#4[_P!UMSZ9>U5B4RC0Y54D28U#LZBTE,DM/P:8EY^0^P'9,4IZ>&D29B %
M)S$NI_RL*/OOW%Q://[1Q>*D*7U! *6"4E+E=7.4V!'$D6NX@VPZ2724NS?>
MB6A7MNQ VEJE[[Y4AJ]%TR>U*FT&RT6NY9J95)>HT5=&C.^-*BF'59-0D>4*
M4%341E4;S<LW"X=$L%*NVZ1DIJ7)<%B+.>#48@:V%VABYTQ69!3+"I@2HC\0
M2Q#)8$,"36M6.C<TL=-CI5RZDSXC=\HK8D[J5FF6Y47ME[QI]9N"A0*U;E)%
MKUZE^(XK5M)>A5&X+@I5="^LETBCQE2*BB8[*97F1A,.$!9(J " 0&+$N[U9
MF.A##2NI,VGCTK* 24A14")9[0! R$58JK6K5>U+K!Z9'2)J=-H'8[I95*N#
M?RHVE15U?9J[J+VK;B*PA53FW@ZBW^"T7(;BE^3\Z.0_51U*Y4D\#ZM$R<+F
M(*2>R2X4X<:-IO<4X$Q"]H8XI"TS GMI!2J3VLI(<YM-; DE@]F]-.B9?ER[
MC;*6[<UU37*G5W:E=$,5=U#;;M6ATVYJM3H$XAI*$KXXD9EL.)0GK0UQJXB2
M3Q\4A 60F@))T(#<?6WF8]-LZ;,FR0J87571G#EBU1;7OK>.G$ESC3Q'D1S'
MH[C@]^,GTX&-8 & &X-&]F!)#-N\_#@]Q$^IBT&D(AC_ '.Q_ M?R$ZE5SS/
MK$)L.0](H994'9'"<*[*QPDD@#+DK/<,@E(*01[$D$@\@09P^_YW1682$*(+
M%J7KKIR[C72/F#Z6U/W*G=*&K)W>F;.U'<2HR=NXUKRK/M;>FY+BVFM^!<;+
M]$K%(J%'J'B:A5NXX*UR9BI:'FVI2U30TECA ]1A,OW-Q3LJ;-JQ:ES2[^H!
MCYIM48E6U2^994J35"J2V (<!/\ ,+N<IO0AH^FVVE&/;E%0ZMV0M%*@!3RD
MK+CRNRM$N.!?GA;A\Y7'Y_$?/\[.O,S"#,6ULQ;NI'TB0DIDR@2YR)?O#Q=N
MW(_ R?@:_P"+5(S0=N1^!D_)?\6D(IR^DDGJI',G^XGZVD( ^WZ6I/P,_2K2
M$*7&CS+4GY(#_;&D(.-G\'('^;^A1TA#5*9S^QRO\EOE_*TA#>)G\',^3/UM
M(1$X(ZB"4S!@8'V/Z5:0AG!'] EX]U !^<DZJ5$*"1J#6OTX/S@SC1N7+WUI
MWQ&MIM> E,K@!!(+7>M)RE1*5 JX>[@5E)SDCTZ@I5F"DJRJI7@'U'SRB^8%
M!00"[\VH[CT.\=\<K[Y]"/HL]))]N7O/LU:MYU1AM+3-8J-);9JS;?G90W/C
M=6^4J)R0XM9X?-& !CI8?:6+D )3,-- 6H6^HN3II8<+%]']FXTE<Z2C,[%1
M4$J+.7<%V[5S6C<(YN/@<O!T<@>C=;8 \T )EC([P04RL8Y^GF3Z.8UMJVWC
MK]<7#,RC07T;NM1N4:2>B.R:_P %+.0Y6=]6%"VOC5XK&O!!>#R8X0UT=;=:
M2DY"1VKNQCO,H<]0.D&T$!NN+<7-=&Y-W-H:QCF=#=B3""J4^@RK(#U8%C>K
M<FBZL>"?Z \;]BV MY&#D<(DG'H']]'F,?U&K_O)CZ_QF/$*(/-A]-W=@7T*
MV"]<.5:?C.F\6\8O,7P8/0=B*^U]BZ&S@#!0)(5WC*@>TG!\U/">1',$8(T_
M>;:3?^9(+Z WJQ% .%:B\$]"-@J?_#%B7/\ $8>?,<(R*/X.3H<0P.HV:H[9
M  "4I>X4XY# 5(SCYSWZ?O)M+_W(9F((4?H:[[O#]P^CX=\(E1-7SDE^/@+=
MQB^1^@5T4H0^P;34QLG'#PH=(SW#/V90'=S'(^YRT'2+:1+C$$#4!P.#@5[Z
MFM#%AT%V Q/W5+@ZS#2AK6]*#E5XRFA=$+H]VW-:G4K;6EHDLX+2UQ"_P%)R
M"E+JBD+!&0>_N]>HF[?VC-24JQ!LP54,+\[[M-=V7#="MC2)@FR\*@,?YEDL
M7W$F@N_?&_O)^E*CLP^I?1$C)0AJ.TTE 92TA24A"&B,%*20E/,'TYQRXJUS
MIBBJ8O-F)-KU#[MP]&:A]-+DR924RY:4@(#,FPN +-0<.%(H:708T9^KPTA2
M(+IAK2AA)5*4X67$NKF*XNL25)#892>0 7CO.(BX2!I=G?5K0^+9U$ILI4R
MQ.9E*2XGM"@MQ38=P%%*%KZO(&2"I)P0/1G4O8%]6];Z/O/]JE)?LDAS5M-U
M*4' ^$4CEAVX[5O'BXLKQIV@2^T?92@2DMEL.AE3A;'>M:D\/"I2U<0("1J0
MHBP'F7LYOP_O$=6=5&MQ<'NI:M;GRBBK^U]GW/*1-K,*=,E(91'#J')#!##9
M/5M<+3B0>%*E)ZPCK",$JSSU14U0(>IO0D"YHVN@=[:156%ES%9E&H#5+4W
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M@VO?KOXPAG22 #)DY'>>M5^;GW:HD(2"&.E0VCZ:7B*ULV@9F[[GO>#M\KA
M[3(R!W]:HCW/3].L0ED**@0Q(+6MRIZ1+U?W]WBW.R)2JQ&4I#R\4RK,IG!U
M14PI;]+5V(I)YMSDM+=6L^P,%*01QG.<)))&XM34U+=['Y:KV._?2_UW"T7
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MA0!%PW!A&65RF^$RB.K[*[;]V2:2YN%4K6JJH-#MV.W4J=3.D':-C0*Q3$7
M\BK0[KA#9N[9B7U(9I-3K4U@D(A.N,53^SW;=O(#@L7:Y8TJ!;PR3$;;EA)0
M2HEKN2FI&4,-0 :@N31J$V+<-WPITBI,63:3='\1+MS>^BU#<QB-:L"H5*9&
M5?Z]H[E@TQ^MNHHM9F)CV"P\RZW(@_V0E3WRDQY#*;I&SB.T+I#BARD@"E;
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M>@U1%,VVJE:JUW4J!8<F0Q;--5?=3B,NTD5>KR9EHU(>*F^N6J-M#!8,EE3
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M$ ]]]*@;M_QA!P =]&JPO5_[7ACC*'DJ2MZ.I"AA32G&>!8Y\G.?$H$'',X
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?A!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g303279g06c59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303279g06c59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    & R^858X0DE-! 0      $X< @   @  ' )0  AR<C,Y,#DX.1P"!0 U
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T(%1O=6-A;B M($9O<FT@4RTS(&%N
M9"!!5$TM=C4X0DE-!"4      !#V2[^GGO[\=\PW=,B^-)?G.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             !0
M RL    & &< ,  V &, -0 Y     0                         !
M          ,K   !0                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !0     !29VAT;&]N9P   RL    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4
M    4F=H=&QO;F<   ,K     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      V2     0   *     _   !X
M=B    UV !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MRH8?^,7ZRT9(/5<,VXA/Z5M5-E5C&]T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\'I2GGW:N]3^R1_@]*4\^[5WJ?V2/\'I2GGW:N]3^R1_@]*4\^[5WJ?V2/\
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M]KJ@MKE4)#26MW'JDMM<H>_5#(X4<.H((&)M>*QD<.?E>+:4J &#U-Y*<;B
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M J0P(R"#GC\50)E920P((."#P0?=BO[Z5\TTI6/B]*>R%CRFYBWB5G"A>?,
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MW#+=-+!$70/)&R9#(OM 1@D88D@$?*//::'OC5M2U:QL9XK(0W,ZQR&.*19
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M4D91D^.,G Y. /B%:_\ LD3?3_(/;S_<VY_ZAZ_;YR=)^[W9_P#5B_PJQ_\
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M-*4TI32E-*55YQ4?XHL>?I#']G9;71'JX_9+K_X!'[1LZY/];;[$-L?TD?\
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M)*)OVZO:KO%UG*K\ZRB[M59990YJKFNM0,TC3S72S]9,@=Y%97SR"N1TX/8
M    # %77;6.E+;QI:VMB;;PP(O#BA9&C(RN&"GKR#DL22Q)8\FJ+<Y\ !_.
M[KGNX7;1F.E8&JZ-RJE_JM 2I<R]+4;-"&BY*1/#KQ\NS:-(UW8V+J6CHUJW
M0;1B+P(]N0C9ND4);:;P1=/6SO[6:[D\*2&6;QE7Q8VZE 8%22PC(5F))8C)
MYR3![_84DFJM?Z9>P6$/C17$-OX$A\&1.EGZ"DBJ$,H+HBJH0-T#"J*ZX,;
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MR)'3K(Q3)M+##K*HD%#R)=2Z=*U*+5;**ZC 5Q[$\?!,4X7#CSPK EDP?J;
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MT>QCL(9IYXHFD9&G*%U61RY0%$1>D,S%<J2.HC., 0-:\%C;BUW>%WEIY"S
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M;Z!3GJ)&?QD?I-/+]_G_ &?HK:&*Z3GN@H9 HJE%H3FL7/(>4;0UN#^X&?\
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?HN0="FJLKVP)=B ]J?JY=F*BO+I^;GUCS_$&E*__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
